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Abstract 
 Large quantities of pure synthetic oligodeoxynucleotides (ODNs) are important 
for preclinical research, drug development, and biological studies. These ODNs are 
synthesized on an automated synthesizer. It is inevitable that the crude ODN product 
contains failure sequences which are not easily removed because they have the same 
properties as the full length ODNs. Current ODN purification methods such as 
polyacrylamide gel electrophoresis (PAGE), reversed-phase high performance liquid 
chromatography (RP HPLC), anion exchange HPLC, and affinity purification can remove 
those impurities. However, they are not suitable for large scale purification due to the 
expensive aspects associated with instrumentation, solvent demand, and high labor costs.  
 To solve these problems, two non-chromatographic ODN purification methods 
have been developed. In the first method, the full-length ODN was tagged with the 
phosphoramidite containing a methacrylamide group and a cleavable linker while the 
failure sequences were not. The full-length ODN was incorporated into a polymer 
through radical acrylamide polymerization whereas failure sequences and other 
impurities were removed by washing. Pure full-length ODN was obtained by cleaving it 
from the polymer. In the second method, the failure sequences were capped by a 
methacrylated phosphoramidite in each synthetic cycle. During purification, the failure 
sequences were separated from the full-length ODN by radical acrylamide 
polymerization. The full-length ODN was obtained via water extraction. For both 
methods, excellent purification yields were achieved and the purity of ODNs was very 
xxvii 
satisfactory. Thus, this new technology is expected to be beneficial for large scale ODN 
purification. 
xxviii 
Chapter 1 
Introduction 
1.1 General Introduction  
 Oligodeoxynucleotide (ODN) is an essential molecule that has high anticipation for 
a wide range of applications including therapeutic development,1 ODN drug production,2 
and biological studies.3 For decades, ODN has been successfully made by automated 
synthesis using phosphoramidite chemistry and solid phase synthesis. After the synthesis, 
crude ODN is cleaved from the solid support containing full-length ODN and impurities 
(small organic molecules and failure sequences). To obtain pure ODN, the crude product 
has to be purified before the applications. 
   The most widely used methods for ODN purification are gel electrophoresis and 
high performance liquid chromatography (HPLC). Although these methods work well in 
academic laboratory, they have disadvantages. They are suitable for small scale but limited 
for large scale ODN purification due to expensive instrument, large volume of harmful 
solvents, and intensive work.  
 From the problems described above, many researchers created alternative methods 
for ODN purification. Those are affinity purification, such as biotin-avidin extraction4 and 
fluorous chromatography.5 However, the methods still suffer from several drawbacks 
including high budget, labor, and timing. They are still not suitable for high-throughput 
purification. 
 
1 
1.2 The new ODN purification technology 
 To overcome the problems, we have developed new ODN purification technology. 
The principle of the new technology utilizes polymerization reaction to separate full-length 
ODN from impurities or remove impurities from full-length ODN. Therefore, it does not 
involve any types of chromatography. The purification is accomplished by simple 
operations, such as shaking, and filtration.  
 There are many polymerization reactions which can be used for ODN purification, 
such as atom transfer radical polymerization (ATRP),6 click polymerization,7 and Diels-
Alder polymerization.8 However, the polymerization reaction that we decided to use is a 
radical acrylamide polymerization. The reaction is exact same as preparation of 
polyacrylamide gel for electrophoresis. It is commonly used in biology and biochemistry 
research. In addition, the reaction involves low-cost materials. Therefore, this reaction is 
suitable for large scale ODN purification. We have designed two simple non-
chromatographic methods which are presented as follows. 
 For the first method, the concept of ODN purification is illustrated in Scheme 1.1. 
During automated synthesis, the full-length ODN will be attached with the designed 
phosphoramidite containing a terminal deoxynucleotide, a polymerizable function, and a 
cleavable linker at 5´-end. However, the failure sequences will not. After the synthesis, 
purification is achieved by polymerization of full-length ODN. Only full-length ODN is 
incorporated into the polymer while the failure sequences are not. Then, the failure 
sequences and other impurities are removed by washing with water. Finally, the pure full-
length ODN will be released by cleaving from the gel. 
2 
  
 
 
 
 
 
 
 
 
Scheme 1.1. General design of the first ODN purification method using catching full-
length ODN by polymerization 
  
 
 
 
  
Polymerization Washing
Crude ODN
Pure ODN
Cleaving from 
polymer
Full-length ODN
Cleavable 
linker Polymerizable 
function
Failure sequence without 
polymerizable function
Extraction
Polymer
Polymer
3 
 The principle of the second method is to catch the failure sequences by 
polymerization. For each synthetic cycle, failure sequences are capped with the 
phosphoramidite consisting of polymerizable group when the full-length ODN is not. Only 
failure sequences are incorporated into the gel. Then, the pure full-length ODN are 
recovered by water extraction. 
Polymerization Extraction
Crude ODN
Pure ODN
Failure 
sequences Polymerizable function
Full-length ODN without 
polymerizable function
Polymer
 
Scheme 1.2. General design of the second ODN purification method using catching 
failure sequences by polymerization 
 
 Two methods are complimentary to each other. For catching full-length ODN, it is 
suitable to purify long sequence ODN because it only requires the designed 
phosphoramidite for coupling at the last synthetic cycle. On the other hand, catching failure 
sequences is appropriate for purification of short sequence ODN since it is necessary to 
cap failure sequences with polymerizable group after each monomer addition. So, cleaving 
step is not required for the second method.  
4 
 According to both methods, we designed three methacrylated phosphoramidites for 
ODN synthesis. These compounds are vital molecules for ODN purification. They are 
stable under ODN synthesis conditions. The compound 1.1 is used for ODN purification 
by catching full-length ODN (The first method). The structure consists of the 
methacylamide group (polymerizable group) for polymerization, the diisopropyl silyl 
acetal group (cleavable linker), and thymidine as a terminal deoxynucleotide (Figure 1.1).  
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Figure 1.1. Phosphoramidite 1.1 
  
 The ODN synthesis using phosphoramidite 1.1 is shown in Scheme 1.3, the 
compound 1.1 will couple at 5´-OH of (n-1)-mer to get n-mer (1.4).The compound 1.1 will 
not be able to couple the failure sequences because the 5´-OH groups are capped with 
capping agent. After cleavage and deprotection, the crude mixture will contain 1.5, failure 
sequences, and small organic molecules. 
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Scheme 1.3. ODN synthesis for catching full-length ODN 
Small Organics+
O OH
5'5'
Capped failure 
sequence
Solid support
(n-1)-mer
R
O
+
Activator
Coupling
O O
5'5'
R
O
P O
O
CN
O
N
NH
O
OOSiON
H
O
N
H 10
O
2. Oxidation
O O
5'5'
R
O
P O
O
CN
O
N
NH
O
OOSiON
H
O
N
H 10
O
O
Cleavage/
deprotection
HO
5'
OH
3' +
Failure sequences
5'
SiON
H
O
N
H 10
O
O OH
3'
5'
SiON
H
O
N
H 10
O
O
5'
n-merCapped failure 
sequence
1.1
1.5
O
O
R
1. Capping with
(R = Acetyl or phenoxyacetyl)
1.4
OH
(n-1)-mer from 
incomplete coupling
Capped failure 
sequences
R O
O
R
O
6 
 As seen in Scheme 1.4, crude ODN will be polymerized by acrylamide radical 
polymerization. Only compound 1.5 which has methacrylamide group will be incorporated 
into the insoluble gel 1.6. Then, failure sequences and small organic molecules will be 
removed by washing with water. Cleaving the diisopropyl silyl acetal group of 1.6 will 
release pure full-length ODN 1.7.  
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Scheme 1.4. Catching full-length ODN by polymerization 
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The phosphoramidite 1.2 (Figure 1.2) containing only methacrylamide group is 
used as a capping agent to purify ODN by catching failure sequences (The second method). 
The method is illustrated in Scheme 1.5. Instead of normal capping agent, the failure 
sequences are capped with 1.2 to give 1.8. Since 5´-end of the full-length ODN is protected, 
it will not be capped by 1.2. After the synthesis, cleavage and deprotection will give crude 
mixture which comprises of failure sequences 1.9, full-length ODN 1.10, and small organic 
molecules.  
 During acrylamide radical polymerization, only 1.9 is polymerized into the gel to 
get insoluble gel (1.11) while the full-length ODN 1.10 is not. After that, water will be used 
to extract 1.10 from the gel. Then, n-BuOH precipitation will removes small organic 
molecules to give 1.10. 
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Figure 1.2. Phosphoramidite 1.2 
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 Scheme 1.5. Catching failure sequences by polymerization 
 
  
 
 
HO OH
5'5'
+
O
OPO
N
NC
Activator
Coupling HO O
5'
5'
Base O
O
Base
DMTrO
DMTrO
P O CN
n-mer
Solid support
n-mer
Failure sequence
n-mer
Success sequence
(n+1)-mer
Activator
Capping
O O
5'
5'
O
O
BaseDMTrO
P O CNO P
ONC
N
H
O
1) Oxidation
2) DetritylationO O
5'
5'
O
O
BaseHO
PPO
O
O
CN
NH
O
O
O CN
HN OH
5'
O
5' 1) Repeat synthetic cycle
2) Cleavage/deprotection
HN
5'
O
OH
3'
HO
5'
OH
3'
+
Acrylamide radical 
polymerization
Full-length ODN
HO
5'
OH
3'
5'
OH
3'
CONH
CONMe2
CONMe2
+
Insoluble gel with 
failure sequences
1) Extraction
2) n-BuOH precipitation
HO
5'
OH
3'
+Small Organics
Small Organics+
1.2
1.9
1.8
1.10
1.101.10
1.11
9 
For the compound 1.3, the functional groups are similar to the compound 1.1 (The 
methacylamide group and the diisopropyl silyl acetal group). So, the method used for ODN 
purification is as same as the first ODN purification method. However, it has the 
bis(hydroxymethyl)malonate group which utilizes phosphate group to be linked at 5´-end 
of ODN.     
Diisopropyl silyl 
acetal group
1.3
OSiON
H
O
N
H 10
O O O
OO
O P
O
N
CN
bis(hydroxymethyl)
malonate groupMethacylamide 
group
Figure 1.3. Phosphoramidite 1.3 
The 5´-phosphorylated ODN synthesis using 1.3 is presented in Scheme 1.6. The 
compound 1.3 will couple with full-length ODN at 5´-end in the last synthetic cycle to get 
1.12. On the other hand, the failure sequences will not be able to couple with 1.3 because 
the 5´-OH groups are already capped with capping agent. After cleavage and deprotection, 
the crude mixture will contain 1.13, failure sequences, and small organic molecules. 
 After the synthesis, crude ODN will be polymerized by polyacrylamide gel 
formation (Scheme 1.7). The ODN 1.13 will be polymerized into the insoluble gel 1.14. 
Then, water will be used to wash impurities. Next, cleaving the diisopropyl silyl acetal 
group will release ODN 1.15. Bis(hydroxymethyl)malonate on the phosphate group will 
be removed using ammonium hydroxide solution at 80 ºC. Lastly, n-BuOH precipitation 
will give pure 1.16.  
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Scheme 1.6. 5´-Phosphorylated ODN synthesis for catching full-length ODN 
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Scheme 1.7. Catching full-length 5´-phosphorylated ODN by polymerization 
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 This dissertation focuses on our ODN purification technology. Background 
information about ODN including applications, synthesis, impurities during the synthesis, 
typical ODN purification methods, and ODN characterization is introduced in Chapter 2.
 The specific task for the new ODN purification technology has been described in 
the subsequent chapters (Chapter 3-6). The synthesis of compound 1.1 and its purification 
method (Catching full-length ODN by polymerization) are reported in Chapter 3. The 
second purification method (Catching failure sequences by polymerization) using the 
capping agent 1.2 is explained in details in Chapter 4. Purification of 5´-phosphorylated 
ODN including the synthesis of phosphoramidite 1.3, long sequence ODN purification, 
and large-scale ODN purification using 1.3 is presented in Chapter 5. In addition, the 
future research plan with alternative acid-labile functional group for new phosphoramidite, 
further studies for catching failure sequences, and peptide purification is summarized in 
Chapter 6. 
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Chapter 2 
History and Background 
2.1 Deoxyribonucleic acid        
 Deoxyribonucleic acid (DNA) is the molecule that contains genetic information for 
development and growth of living cells. DNA was discovered in 1869 by Friedrich 
Miescher.1 He reported that there was an unknown material isolated from cell’s nuclei. The 
properties of the substance were not as same as proteins or any recognized molecules. For 
example, protease pepsin could not digest this compound. Elemental analysis showed the 
material contains carbon, nitrogen, oxygen, and hydrogen. However, it did not contain 
sulfur but significant amount of phosphorus.  In addition, the compound was dissolved in 
basic solution and was precipitated in acidic or alkaline solutions. According to the 
isolation the material from the cell nuclei, he named DNA “nuclein”. He and his co-
workers, Felix Hoppe-Seyler and P. Plosz, published the manuscript in 1871.  After the 
discovery, Miescher continued analyzing DNA from animal’s cells and he found very 
interesting information. For instance, he was able to confirm that nuclein is in the form of 
phosphoric acid. Furthermore, he could estimate the atomic formula of nuclein in salmon 
sperm. Despite his success to obtain the analyses, Miescher never returned to find the 
conclusion of nuclein.  
Since Miescher’s discovery, some scientists were interested to investigate more 
information about DNA. In 1890s, Albrecht Kossel isolated four nucleobases: adenine, 
cytosine, guanine, and thymine which are DNA’s key components. Later, Phoebus Levene 
was able to identify that each unit of DNA contains nucleobase and 2'-deoxyribose. In 
16 
1953, James Watson and Francis Crick proposed three dimensional structure of DNA based 
on the X-ray diffraction image (Figure 2.1).2 The picture was taken by Rosalind Franklin 
and Maurice Wilkins. They found that there are two strands of DNA existing in the form 
of double helix (Figure 2.2).   
 
 
  
 
 
 
 
Figure 2.1. X-ray diffraction image of DNA [Reprinted by permission from Macmillan 
Publishers Ltd: Nature 1953, 171 (4356), 737-738, copyright 1953. See Appendix D. 
Permission from publishers.] 
 
Double-stranded DNA consists of two deoxyribonucleic acid strands. Each strand 
has the backbone of deoxynucleotide. Each deoxynucleotide contains deoxynucleoside and 
phosphate group. The nucleoside comprises of 2'-deoxyribose (pentose sugar) and 
heterocyclic nucleobase (Figure 2.3).3 The nucleobase and deoxyribose are connected 
???????????????-glycosidic bond. There are two types of nucleobases in DNA: purines and 
17 
pyrimidines (Table 2.1). Purines are the heterocyclic compounds containing both being 
fused fived- and sixed-membered rings. They are adenine (A) and guanine (G).  
Pyrimidines are sixed-membered ring heterocyclic compounds. They are cytosine 
(C) and thymine (T). Each deoxynucleotide has bonded with phosphate diester at 5' 
hydroxyl group to attach one unit and 3' hydroxyl group to attach the next unit. Both DNA 
strands have the specific sequences which are complementary to each other. They are held 
together by two weak forces: hydrogen bonding and nucleobase stacking interaction. Each 
nucleobase has the specific base pairing and number of hydrogen bonds. For example, 
adenine (A) and thymine (T) are formed with two hydrogen bonds, whereas cytosine (C) 
and guanine (G) are formed with three hydrogen bonds (Figure 2.4).4 
 
 
 
 
 
 
 
 
 
Figure 2.2. Double helical structure of DNA 
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Figure 2.3. Nucleosides and Nucleotides in DNA 
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Table 2.1. Purine and pyrimidine bases in DNA 
 
 
 
 
 
 
 
 
 
Figure 2.4. Hydrogen bonding for each base pair in double-stranded DNA 
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2.2 Oligodeoxynucleotide and applications 
Oligonudeoxycleotide (ODN) is short single-stranded DNA. It has been widely 
used in medical and scientific research. Examples include antisense ODN drug, DNA 
sequencing, Polymerase Chain Reaction (PCR), and synthetic biology for total gene 
synthesis.  
2.2.1 Antisense ODN  
The concept of antisense ODN is based on DNA-DNA or DNA-mRNA 
hybridization. The antisense sequence is designed and synthesized to selectively hybridize 
to the complementary strand of DNA or mRNA (It is also called sense sequence).5 After 
binding the target sequence, transcription or translation process will be terminated. This 
can suppress abnormal gene expression that can cause diseases. There are two ODN drugs 
on the market. Fomivirsen (Commercial name is Vitravene) is the first one that was 
approved by United States Food and Drug Administration (FDA) in 1998. Fomivirsen 
contains 21-mer oligodeoxynucleotides (Figure 2.5.1) that can be used to cure 
Cytomegalovirus retinitis (Inflammatory retina).6 The structure contains phosphothiorate 
diester bond instead of phosphate diester bond. So, the compound is resistant to degradation 
by nucleases. In addition, Mipomersen (Commercial name is Kynamro) is the other 
antisense ODN drug that FDA has been approved in 2013. This drug has a specific 
sequence to hybridize to messenger RNA of Apolipoprotein B.7 Therefore, it can reduce 
Familial hypercholesterolemia (Cholesterol in blood stream).  
21 
The structure of Mipomersen contains 2'-deoxyribosenucleotides and 2'-O-
methoxyethyl-modified ribonucleotides linked with phosphothiorate bonds (Figure 2.5.2). 
It’s commercially available in a form of sodium phosphothiorate.  
 
 
Figure 2.5.(1) structure of Fomivirsen (5'-GCG TTT GCT CTT CTTCTT GCG-3'), (2) 
structure of  Mipomersen (5'-G*-C*-C*-U*-C*-AGTCTG-d(5-methyl-C)-TT-d(5-
methyl-C)-G*-C*-A*-C*-C*-3')[* = 2'-O-(2-methoxyethyl)] 
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2.2.2 DNA sequencing 
Another important application of ODN is DNA sequencing. DNA sequencing is to 
determine the order of deoxynucleotides in DNA sequence. One of the DNA sequencing 
methods that requires ODN is the Sanger method.8 It was created by Frederick Sanger and 
co-workers in 1977. The DNA sample is divided into four portions. Each portion contains 
ODN primers, DNA polymerase, and four standard deoxynucleosidetriphosphates (dNTPs) 
(dNTPs are dATP, dGTP, dCTP, and dTTP). However, only one of the modified 
dideoxynucleosidetriphosphates (ddNTP) (ddNTP is ddATP, ddGTP, ddCTP, or ddTTP) 
is added to each portion. These ddNTP are radioactively labeled or fluorescently labeled. 
The ODN primers hybridize to the target sequence. Then, DNA is elongated by coupling 
to dNTPs with polymerase catalysis. During elongation, ddNTP, which does not have 3´-
OH group, is also incorperated into DNA, so it ceases the elongation. Heat-initiated 
denaturation releases DNA fragments from target strand. Those fragments are separated by 
gel electrophoresis. With the gel image of the different fragments from each portion, the 
target sequence of DNA is determined.   
2.2.3 Polymerase chain reaction (PCR) 
PCR also has to use ODN as a primer. It is a commonly used technique that can 
amplify DNA by producing numerous copies of a specific DNA sequence. This technology 
had been established in 1983 by Kary Mullis.9 The concept of PCR is to synthesize a 
complementary DNA strand according to the template strand. First of all, double-stranded 
DNA is heated to separate the two template strands. After that, primers (short ODN 
sequences that are complementary to the 3´ segment of the template sequences) bind to 
each template sequence at 3´-end. The next process is called elongation. DNA polymerase 
23 
synthesizes complementary DNA on the template sequence. Each new deoxynucleotide is 
added from 3´-end to 5´-end. Then, the process is terminated when the synthesis has 
reached to 5´-end. The process is usually repeated for multiple times. After PCR, a 
specific DNA sequence will be gathered in million to billion copies.       
2.2.4 Total gene synthesis 
Total gene synthesis requires thousands of ODNs. Gene synthesis is an important 
application for many areas of DNA technology, such as mutagenesis studies, gene 
expression, and gene engineering, etc. It is the method to make artificial genes using a 
combination of chemical reactions and biological technique. Since genes consists of very 
long double-stranded DNA, the synthesis needs to be partial ODN synthesis before 
assembling together. Firstly, sets of uniquely designed ODN segments are synthesized 
using solid phase synthesis with phosphoramidite chemistry. After ODNs are purified, each 
ODN segment is connected to each other using polymerase and precise annealing to get a 
complete genes.10 Currently, some researchers use PCR to improve the method which 
lower the cost and errors during the synthesis.11     
Furthermore, many ODN drug development projects are still underway. Large 
quantities of ODN have been highly demanded. As a result, ODN synthesis is essential for 
this research area as well. 
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2.3 ODN Synthesis 
 Due to the high demand of ODN, synthesis of ODN has become important. In the 
history of ODN synthesis, many scientists were interested to develop ODN synthesis 
methods using chemical reactions. Some methods have been successful and people are still 
using them. However, some of them have drawbacks and people are no longer using those 
methods. The history of ODN synthesis is briefly summarized below. 
2.3.1 First ODN Synthesis Method       
Todd and Michelson published the first ODN synthesis method in 1955.12 They 
reported the synthesis of dithymidyldeoxynucleotide using phosphorylchloridate method 
(Scheme 2.1). In the reaction, a phosphate linkage between two thymidines using 5?-
benzoyl-3?-phosphonyl thymidine (2.4) and 3?-benzoyl thymidine (2.5) in the presence of 
2,6-lutidine was formed. The mechanism of the synthesis is illustrated in Scheme 2.2. First, 
3?-hydroxyl group of 2.1 was phosphonated with benzyl phosphonic diphenyl phosphoric 
anhydride to get H-phosphonate 2.2. The compound 2.2 can be tautomerized to get 
hydroxyphosphite 2.3 and was then converted to 2.4 using N-chlorosuccinimide. Next, 5?-
hydroxyl group of 2.5 was coupled with the compound 2.4 to obtain 2.6 as a product. The 
synthesis appeared to be interesting. Nevertheless, there were some flaws in this method. 
In their report, the reaction between 2.4 and 2.5 was indeed slow. In addition, the 
phosphoryl chloride 2.4 was not stable since it could be hydrolyzed in the presence of 
moisture to get phosphoric acid. Therefore, 2.4 had to be generated in situ prior to coupling. 
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Scheme 2.1. First ODN Synthesis 
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2.3.2 Phosphodiester Method 
 In 1958, Khorana and his colleagues had developed the ODN synthesis after Todd 
and Michelson’s work. They introduced the phosphodiester method to synthesize ODN 
instead of preparing the hydrolysable phosphochloridates.13 Later, they published the 
synthesis of 72-mer transfer ribonucleic acid (tRNA) using this method in 1970. The 
concept of the reaction is similar to a peptide coupling reaction. It is a condensation 
between reactants such as 5´-O-DMTr deoxynucleoside-3´-O-phosphate 2.7 and 
deoxynucleoside 2.9 using dicyclohexylcarbodiimide (DCC) as a coupling agent (Scheme 
2.3). 
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Scheme 2.3. ODN synthesis using phosphodiester method 
 
The mechanism is shown in Scheme 2.4. The phosphate group of 2.7 is activated 
with DCC to get the intermediate 2.8. Then, the free 5´-hydroxyl group of 2.9 is coupled 
with 2.8 to give dideoxynucleoside phosphate 2.10 and 1,3-dicyclohexylurea (2.11) as a 
side product. 
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Scheme 2.4. Mechanism of ODN synthesis using phosphodiester method 
Despite their success, Khorona and co-workers had found shortcomings. For 
instance, branched ODN was a major side-product during the synthesis. It was generated 
from the coupling between interdeoxynucleotide phosphate linkages and intermediate 2.8 
(Scheme 2.5). Consequently, a laborious multi-step purification process was followed to 
remove branched contaminants after coupling. The other drawback was the long coupling 
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time. They reported that coupling reaction between 2.8 and 2.9 took up to two days to get 
a good yield. That would be a serious problem when this method was used to synthesize 
long strand ODN. 
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2.3.3 Introduction of Solid Support for ODN Synthesis 
After successful peptide synthesis, solid-phase chemistry had been applied to the 
ODN synthesis. Robert Letsinger firstly introduced dimer and trimer ODN synthesis using 
solid support in 1963. In his paper, styrene-divinyl benzene polymer was used as a solid 
support to attach deoxycytidine (Scheme 2.6).14 Since 3´-hydroxyl group and 5´-hydroxyl 
group of 2.12 were protected with benzoyl group and DMTr group respectively, the amino 
group was coupled with 2.13 to give 2.14. ODN could be synthesized on this support by 
removal of DMTr group. Then, 5´-hydroxyl group would be ready for the next coupling 
with the other deoxynucleotide. Letsinger used the phosphotriester method for the 
synthesis. After the synthesis is complete, ODN was cleaved from the support with a strong 
base.  
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Scheme 2.6. Preparation of solid support using 5´-DMTr-protected dC. 
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 Later, Letsinger found the best way to attach the initial nucleoside to the solid 
support. Instead of attaching to the amino group of nucleobase, the solid support was linked 
to the 3´-hydroxyl group of the nucleoside via an ester bond (Figure 2.6). Since the ester 
bond is more easily cleaved than the amide bond of the previous solid support (see 2.14), 
the new approach has been commonly used until nowadays. However, support swelling in 
organic solvent was still a main issue of the support. 
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Figure 2.6. The new version of solid support attaching to 3´-end of the initial nucleoside 
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2.3.4 Phosphotriester Method 
Phosphotriester method was published in 1969 by Letsinger and Ogilvie.15 The 
reaction is a coupling between reactants such as 5´-O-DMTr-deoxynucleoside 2.15 and 
deoxynucleoside-linked solid support 2.18 (Scheme 2.7). Mesitylsulfonyl nitrotriazole 
2.16 (MSNT) was used as the coupling agent. The synthesis is similar to phosphodiester 
method, but the advantage is that the phosphate group 2.16 was protected by a 2-cyanoethyl 
group. This avoided branched ODN which was generated in the previous version of 
phosphodiester method.  In addition, 2-cyanoethyl group was simply removed with 
ammonium hydroxide (NH4OH). 
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Scheme 2.7. ODN synthesis using phosphotriester method 
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The mechanism of the synthesis is shown in Scheme 2.8. The phosphate group of 
2.15 is reacted with 2.16 to get mixed anhydride 2.17. Then, 5´-hydroxyl group of 2.18 is 
coupled with 2.17 to obtain 2.19 as a product.  
However, the major problem of this method was the coupling time. The coupling 
reaction acquired more than one and a half hour to complete. The other drawback is that 
the coupling is inefficient. It was reported that the average step-wise yield was low from 
the coupling step. Therefore, the method could not be used to synthesize ODN longer than 
20-mer.  
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Scheme 2.8. Mechanism of ODN synthesis using phosphotriester method 
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2.35 H-Phosphonate Method 
Todd and Michelson’s work on the first ODN synthesis motivated many researchers. 
Later, a new ODN synthetic method had been developed by two other research groups 
(Roger Stromberg’s group and Mark Matteucci’s group).16 This method used the H-
Phosphonate chemistry. As shown in scheme 2.9, 3'-H-phosphonate-2'-deoxynucleoside 
(2.20) and 2.18 were used as starting materials to form the phosphonate 
interdeoxynucleotide linkage in 2.22. Pivaloyl chloride is a coupling agent to form 
phosphonate bond. The mechanism of the synthesis was presented in scheme 2.10. 
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Scheme 2.9. ODN synthesis using H-phosphonate method 
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According to the Scheme 2.10, the compound 2.20 was acylated with pivaloyl 
chloride to get the intermediate 2.21 in the form of mixed phosphonic carboxylic 
anhydride. After that, 5´-hydroxyl group of 2.18 was coupled with 2.21 to obtain the 
phosphonate 2.22. Then, H-phosphonate 2.22 in the form of phosphorus (V) is converted 
to reactive hydroxyphosphite 2.23 in the form of phosphorus (III) via tautomerization. 
Next, the lone-pair electrons of phosphorus react with iodine to get iodophosphonium 2.24. 
Proton absorption using pyridine retrieves iodophosphate 2.25. Finally, hydrolysis of 2.25 
in the presence of water and pyridine gives deoxynucleotide 2.26. 
This approach has a major problem. H-phosphonate activation can cause side 
reactions.17 For example, the reaction requires two to five equivalents of pivaloyl chloride 
to achieve the high yield of product. The excess amount of pivaloyl chloride can cause 
acylation of phosphonate 2.22 to get acylphosphonate 2.27 (Scheme 2.11). Also, 
compound 2.20 can be acylated twice to produce bis-acyl phosphate 2.28.  Then, 2.28 can 
react with two equivalents of 2.18 to form phosphitetriester 2.29 (Scheme 2.12). That will 
lower yield of the product because their side products cannot convert to get ODN 2.26. 
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Scheme 2.11. Phosphonate acylation (side reaction) of H-phosphonate compound 
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Scheme 2.12. Double acylation (side reaction) of H-phosphonate group 
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2.3.6 Phosphite-triester Method 
 Since previous methods were suffering from side reactions and long coupling time, 
researcher tried to find ODN synthesis methods that are more effective than the former 
methods. In 1975, Letsinger and co-workers published the new ODN synthesis method 
called phosphite-triester method (Scheme 2.13).18 The concept of this reaction is using 
phosphorus (III) intermediate for coupling instead of phosphorus (V) intermediate. This is 
because phosphorus (III) compound has much higher reactivity than phosphorus (V) 
species. Therefore, the reaction time can be significantly reduced and the synthesis can be 
achieved in higher yields. 
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Scheme 2.13. ODN synthesis using phosphite-triester approach 
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As illustrated in Scheme 2.14, 5´-hydroxyl group of 2.31 was reacted with 
phosphomonochloridite 2.30 via bimolecular nucleophilic substitution (SN2). Then, 
pyridine absorbed proton to give 2.32. The phosphorus of intermediate 2.32 is oxidized by 
iodine to get iodophosphonium 2.33. Then, water is used to hydrolyze 2.33 in the presence 
of pyridine to give phosphate trimester 2.34 as a product. 
The major problem of this method is that the phosphomonochloridite is very 
sensitive to air. The lone-paired electrons on phosphorus can quickly react with oxygen to 
form inactive phosphate triester. It can also be hydrolyzed by moisture in air. Thus, the 
intermediate has to be freshly prepared for ODN synthesis. 
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2.3.6 Contemporary ODN synthesis    
By the time of early 1980s, there were two major problems for solid phase ODN 
synthesis. First, the organic polymer supports (see section 2.3.3) swells in organic solvents. 
That could block the flow of reagents and solvents when applying to the automated 
synthesis. Second, the nucleoside intermediates such as phosphonyl nucleoside (see section 
2.3.1) and    phosphomonochloridite (see section 2.3.6) were not stable. In early 1980s, a 
new approach of ODN synthesis, which successfully eliminated these problems, had been 
developed by Caruthers’ research group.19 The support swelling problem was resolved by 
using controlled pore glass (CPG). The other problem was overcome by phosphoramidite 
chemistry. The concept of the reaction resembles phosphite-triester method. However, they 
changed the leaving group of phosphorus (III) compound from chloride to a diisopropyl 
amino group. 2-Cyanoethyl (CE) group was used to replace the o-chlorophenyl protecting 
group. This is very magnificent because phosphoramidites are stable in a form of solid. It 
can be prepared beforehand and stored properly until needed. As a result, this approach is 
convenient for researchers and it has become widely used for decades.20   
There are four deoxynucleoside phosphoramidites for ODN synthesis: 
deoxyadenosine (dA) phosphoramidite, deoxyguanosine (dG) phosphoramidite, 
deoxycytidine (dC) phosphoramidite, deoxythymidine (dT) phosphoramidite (Figure 2.7). 
5´-OH group of each phosphoramidite is also protected with 4,4´-dimethoxytrityl (DMTr) 
group. The exocyclic amino groups of dA, dC, and dG are protected to prevent side 
reactions during the coupling step. For stanadard ODN synthesis, the amino group of dA 
is protected by benzoyl (Bz) group. The amino group of dG is protected by isobutyryl (i-
44 
Bu) group. The amino group of dC is protected by acetyl (Ac) group. Because dT does not 
have exocyclic amino group, it does not need any protection.  For ultramild ODN 
synthesis, dC phosphoramidite and dT phosphoramidite are the same as those used in the 
standard ODN synthesis. However, the amino groups of dA and dG are protected by 
phenoxyacetyl (Pac) group and 4-isopropyl-phenoxyacetyl (i-Pr-Pac) group respectively 
(Figure 2.8).  
 Later, Caruthers and Hood developed automated system for ODN synthesis. The 
system combined solid phase synthesis and phosphoramidite chemistry. During 
collaboration, they formed a company named Applied Biosystems, Incorporated (ABI). 
They also exploited the first phosphoramidite DNA synthesizer which benefits to ODN 
research nowadays. The concept of automated synthesis is a synthetic cycle. For each 
cycle, addition of phosphoramidite takes place at 5´-end of ODN strand. The synthesis 
continues until the chosen sequence is complete. ODN synthetic cycle is illustrated in 
Scheme 2.15. It contains four steps that are described in the next section.  
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2.3.7 ODN synthetic cycle 
2.3.7.1 Detritylation 
4,4´-Dimethoxytrityl (DMTr) group, which protects 5´-hydroxyl group of the initial 
deoxynucleoside, is removed in this step. Therefore, the incoming phosphoramidite 
monomer can couple at 5´ end. DMTr group is acid-labile enough that can be cleaved using 
acidic solution (2-3 %), such as dichloroacetic acid or trichloroacetic acid in 
dichloromethane. The mechanism of detritylation is shown in Scheme 2.16. Oxygen atom 
at 5´ position of 2.35 is protonated by the acid. Then, orange-colored DMTr cation (2.37) 
is released from the CPG-linked nucleoside to get 2.36. The cation is stable because it can 
form several resonance structures (Scheme 2.17). 
 
Scheme 2.16. Mechanism of detritylation 
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Scheme 2.17. Resonance structures of DMTr cation 
 
2.3.7.2 Coupling 
 When detritylation is finished, the solution of phosphoramidite monomer is 
delivered. The phosphoramidite is activated by a weak acid catalyst such as 1H-tetrazole, 
4,5-dicyanoimidazole (DCI), etc. Then, the activated phosphoramidite is coupled at 5?-
hydroxyl group of CPG-linked nucleoside. The most common weak acid used for 
activation is 1H-tetrazole. The pKa of 1H-tetrazole is 4.9, which is adequately acidic to 
activate phosphoramidite but not acidic enough to deprotect DMTr group. However, some 
researchers considered 1H-tetrazole as an explosive compound.21 In addition, there were 
reports that 1H-tetrazole could cause premature detritylation, which results addition 
sequences, so replacing it with the other activating agent, such as 4,5-dicyanoimidazole 
(DCI) was pursued.22 Although DCI is less acidic than 1H-tetrazole (pKa = 5.2), it can 
activate phosphoramidite efficiently. It is also less harmful than 1H-tetrazole for large-
scale ODN synthesis.  
 The mechanism of phosphoramidite activation and coupling is proposed in 
Scheme 2.18, the diisopropylamino group in 2.38 is protonated by 1H-tetrazole to generate 
a good leaving group of diisopropylammonium. Next, tetrazole anion is acted as a 
nucleophile to displace the diisopropylammonium to get 2.39 and diisopropylamine. Then, 
O
O
O
O
O
O
More
2.37
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5´ hydroxyl group of 2.36 attacks to the P(III) atom of 2.39 to form phosphite-triester 2.40. 
In the final step, the proton is absorbed by diisopropylamine to form 2.41 as a side product.  
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Scheme 2.18. Mechanism of phosphoramidite activation and coupling 
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2.3.7.3 Capping 
In spite of rapid coupling of phosphoramidite, it is inevitable that the reaction 
cannot be 100 % complete. There are a few unreacted 5'-unreacted hydroxyl groups, which 
result from failed coupling. These can be available to react with the phosphoramidite 
monomer in the next cycle. This will generate deletion sequences that miss one nucleotide 
(Figure 2.9). If the ODN synthesis is left unchecked, deletion sequences accumulate from 
each synthetic cycle. The final ODN crude product would contain a complexed mixture of 
full-length sequence and deletion sequences. That would make purification very 
challenging.  
 
CAGATTCGTCO OH
5'3'
CAGATTCTCO OH
5'3'
O
NH
O
O
NH
O
 
Figure 2.9. Example of deletion sequence (right). The dG at 8th position was missing 
compared to the full-length sequence (left) 
 
To solve the problem, 5'-unreacted hydroxyl groups are blocked using a capping 
agent to terminate the failure sequences. There are two standard capping solutions on DNA 
synthesizer. One is the mixture of acetic anhydride and small amount of pyridine in THF. 
The other is N-methylimidazole (NMI) in THF. For Ultramild synthesis, phenoxyacetic 
anhydride is used instead of acetic anhydride because it avoids undesired side reactions. 
During capping, these two solutions are delivered to the synthesis column at the same time. 
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The mechanism is shown in Scheme 2.19. 1-Methylimidazole is reacted with acid 
anhydride to get intermediate 2.42. Then, unreacted 5'-hydroxyl group of 2.36 is acylated 
with 2.42 to get capped ODN 2.43.  
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Scheme 2.19. Mechanism of capping 
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2.3.7.4 Oxidation          
  The newly formed phosphite-triester bond, which contains phosphorus (III), 
is not stable to acid. So, it has to be converted to stable phosphorus (V) species by oxidation 
before detritylation of the next cycle. The standard oxidizing agent, which is commonly 
used, consists of iodine (I2), water, and organic weak base (pyridine, 2,6-lutidine, or 
collidine) in THF. The mechanism is shown in Scheme 2.20. Phosphite-triester 2.40 is 
transformed to iodophosphonium 2.44 by iodine. Then, hydrolysis of 2.44 using water and 
proton removal using pyridine gives product 2.45. Since the next coupling reaction could 
be inhibited by water residue from the oxidizing agent, some researchers prefer to carry 
out the capping step after oxidation. Thereby, the solid support could be more likely to be 
dry before the next cycle.  
Alternative oxidizing agents have been studied. For example, some researchers had 
developed non-aqueous oxidizing agents for anhydrous conditions. Examples include tert-
butyl hydroperoxide (t-BuOOH), cumene hydroperoxide, bis-trimethylsilyl peroxide, etc.23 
However, these are not widely used because they are not stable. All of them must be 
prepared prior to use for the synthesis. (1S)-(+)-(10-Camphorsulfonyl)-oxaziridine (CSO) 
is the other commercially available non-aqueous oxidizer. It is very useful for synthesis of 
certain special ODNs which can be degraded by iodine. Examples include DNA-
phosphonoacetate,24 and ODN containing 7-deaza-deoxyguanosine.25  
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2.3.8 Cleavage and Deprotection 
 The previous four steps are repeated as one cycle for adding each nucleoside 
phosphoramidite monomer until the ODN synthesis is complete. After that, ODN on the 
solid support, which is attached to CPG, is released from the solid support by linker 
cleavage. Also, all of the protecting groups on the nucleobases and phosphates are 
deprotected. These are achieved using concentrated ammonium hydroxide (NH4OH, 28%) 
solution. Ammonium hydroxide is the most widely used reagent for this step because it can 
cleave and deprotect ODN simultaneously. As seen in Scheme 2.21, mechanisms are 
described in the followings:    
2.3.8.1 Cleavage ODN from solid support 
 The succinyl ester linker, which connects 3´-end of synthetic ODN to CPG, is 
readily cleaved by aminolysis. In the Scheme, ammonia acts as a nucleophile to react the 
carbonyl group of succinyl ester. Then, the ODN is cleaved from the CPG. For automated 
synthesis, ammonium hydroxide solution is usually delivered to the CPG for four times. 
Each time, cleavage reaction is allowed to proceed for 15 minutes. Argon was used to flush 
the ODN solution to a glass vial. Manual cleavage of ODN can also be achieved by shaking 
the CPG with ammonium hydroxide solution.   
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2.3.8.2 Phosphate deprotection 
The 2-cyanoethyl groups, which protect phosphate groups during the entire 
??????????????????????? ?????????????????????????????????????????-carbon next to cyano-
group ???????????????????????????????????????????-elimination gives ODN in a form of 
ammonium phosphate and acrylonitrile as a by-product. In addition, 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), which is a non-nucleophilic base, can also be used 
for deprotecting 2-cyanoethyl groups.    
2.3.8.3 Nucleobase deprotection 
 Protecting groups on nucleobases are deprotected by simple amide aminolysis. For 
normal conditions, the nucleobase with standard protecting group is treated in ammonium 
hydroxide solution at 55º C for 8 to 15 hours. For Ultramild conditions, protecting groups 
can be removed in the same solution but room temperature for 1 to 2 hours. 
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Scheme 2.21. Mechanism of cleavage, phosphate deprotection, and nucleobase 
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2.3.8.4 Quenching of by-product  
 Acrylonitrile, which is generated from phosphate deprotection, is a Michael 
acceptor. It is reactive enough to react with nucleobases through Michael addition at room 
temperature. That causes undesired and modified ODN. As illustrated in Scheme 2.22, 
amino group of adenine, cytidine, and guanine can react with acrylonitrile to get 2-
cyanoethyl adduct. Michael addition of thymine needs ammonia to deprotonate the proton 
at N-3 position of thymine. Then, the nucleophile reacts acrylonitrile to get the thymine 
adduct (Scheme 2.23). 
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Scheme 2.23. Michael addition of acrylonitrile to thymine 
 
Since Michael addition is a reversible reaction, un-modified nucleobases can be 
retrieved by NH4OH. Excess ammonia will deprotonate the proton on the carbon which is 
next to the electron withdrawing cyano-??????????????-elimination would give unmodified 
nucleobases (Scheme 2.24). The excess ammonia also scavenges the remaining 
acrylonitrile to give 3-aminopropanenitrile which is no longer Michael acceptor (Scheme 
2.25).  
Some researchers adjusted the method to avoid Michael adducts. This was achieved 
by completing phosphate deprotection before cleavage and nucleobase deprotection. CPG-
bound ODN was treated with an organic weak base in an organic solvent, such as 10 % 
diethylamine in acetonitrile, 10 % DBU in acetonitrile, or 1:1 triethylamine/acetonitrile. 
Phosphate groups are deprotected while ODN remains on the CPG. Acrylonitrile cannot 
react any nucleobases which are still protected. Thus, it will be washed away by the organic 
solvent.  
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2.4 Impurities in Crude ODN 
 After automated synthesis, final crude ODN contains the mixture of full-length 
ODN and other impurities. The amount of impurities and the yield of pure ODN depends 
on quantity of synthesis, quality of solvents and reagents, and cautiousness of operating 
automated synthesizer. For instance, 20-mer ODN synthesis typically contains 40-70% of 
full-length ODN and 30-60 % of impurities. There are several types of impurities in crude 
ODN.26    
2.4.1 Small Organic Molecules 
Mostly, they are generated from removing the protecting groups. Examples include 
acetamide, benzylamide, isobutylamide, 3-aminopropanenitrile etc. Since they are neutral 
molecules, they can be easily removed by ethanol or n-BuOH precipitation27 from an 
aqueous buffer. ODN, which is negative charged in the buffer, is insoluble in ethanol or n-
BuOH. Then, ODN is precipitated. The small molecules are soluble and remaining in the 
supernatant. Besides precipitation, size-exclusion chromatography can be used to remove 
small organic molecules (See 2.5.1).  
2.4.2 Failure Sequences 
2.4.2.1 Usual failure sequences  
They are generated from the coupling step due to incomplete coupling. The longer 
the strand of ODN is synthesized, the more failure sequences are produced. Those 
sequences will be capped with a capping agent, such as acetic anhydride, or phonoxyacetic 
anhydride (For Ultramild conditions) to stop elongation which cause deletion sequences. 
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Because the properties of the failure sequences are similar as the full-length ODN, 
removing failure sequences are challenging.  
2.4.2.2 Unusual failure sequences        
 (1) Deletion sequences  
They can be produced from incomplete capping. The failure sequences without 
capping still have free 5´-OH groups. These hydroxyl groups can couple with the coming 
phosphoramidite monomer in the next synthesis cycles. Hence, the sequences will be 
missing a nucleotide (Scheme 2.26).  
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Scheme 2.26. Formation of deletion sequence 
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(2) Addition sequences 
 Addition sequences are the sequences that contain one or more extra nucleobases. 
They are resulted from premature detritylation. So, the phosphoramidite monomer can be 
added to the ODN strand twice (Scheme 2.27).    
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Scheme 2.27. Formation of addition sequence during coupling step 
For deletion sequences and addition sequences, they are very difficult to remove. 
Luckily, they occur in very small amount in crude ODN because the conditions for 
contemporary ODN synthesis have been designed to prevent this type of impurities. Thus, 
the main task of ODN purification is focusing on removing failure sequences from the full-
length ODN. 
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2.5 Current Methods for ODN Purification and Limitations 
 Purification is a major task for ODN production for many applications. Typically, 
there are several methods to purify crude ODN. 
2.5.1 Size-exclusion Chromatography 
The principle of size-exclusion chromatography is separation of molecules by size. 
The packing material in the column contains a lot of pores. When crude ODN solution is 
loaded, smaller molecules enter deeply in the pores. So, they are eluted out slowly. On the 
other hand, ODN cannot penetrate in those pores because it is a larger molecule. Thus, it 
is eluted quickly through the column.  
Size-exclusion Chromatography works well for the separation of ODN from small 
organic molecules with a minimum volume of eluate. Nevertheless, the method has a 
problem. The method cannot separate impurities which their sizes are similar to the size of 
full-length ODN. In addition, the method gives a good resolution when doing small scale. 
Large scale purification using this chromatography can cause a poor resolution. 
2.5.2 Polyacrylamide Gel Electrophoresis (PAGE)  
PAGE has the best resolution to separate pure ODN from impurities. It is suitable 
to purify ODN containing more than 60 nucleobases. It can separate and retrieve pure ODN 
depending on charges on the molecules. The method requires polyacrylamide gel.  Despite 
high purity of ODN, this method is mostly used for qualitative analysis (μg-mg). For 
purification, only at very small scale is applicable. 
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2.5.3 High Performance Liquid Chromatography (HPLC)  
HPLC is the most popular method for quantitative and qualitative analysis of ODN. 
The separation using the method is based on the properties of ODN and column absorbents. 
There are two kinds of HPLC that are used to purify ODN: reverse-phase HPLC and ion-
exchange HPLC. 
2.5.3.1 Reverse-phase HPLC (RP-HPLC) 
The separation using RP-HPLC is based on the difference of hydrophobic 
interaction between absorbent and compound when the sample is eluted by a mobile phase. 
For absorbent, it is the modified silica containing hydrophobic long-chain alkyl group (eg. 
-C18H37 or -C8H17). There are two standard mobile phases required for elution. One is a 
polar mobile phase (usually 0.1 M triethyl ammonium acetate). The other is a non-polar 
mobile phase (usually 90-100% acetonitrile). The elution will typically be gradient 
beginning from 100 % polar mobile phase to 100 % non-polar mobile phase.  
After automated synthesis, the 5´-end of full-length ODN contains DMTr group 
while impurities (failure sequences and small organic molecules) do not. Since DMTr 
group is hydrophobic, so the interaction of DMTr-on ODN with the absorbent is stronger 
than that of impurities during gradient elution. Therefore, impurities are eluted out before 
pure DMTr-on ODN is eluted. After separation, DMTr group on full-length ODN is 
removed by detritylation (usually 80% acetic acid) to give pure ODN. However, this 
method has some drawbacks. It requires large amount of solvent, expensive HPLC column 
and machine. Also, it is time-consuming to finish purification in the large batches. 
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2.5.3.2 Ion-exchange HPLC (IX-HPLC) 
IX-HPLC is the other HPLC method that can purify ODN. It is based on the charges 
interactions between ODN and the ions stationary phase. An additional drawback of this 
method is the eluent containing non-vaporizable salts. Consequently, the purified ODN 
needs to be desalted which requires another step before use.   
2.5.4 ODN Cartridge Purification 
 The concept of cartridge purification is similar to RP-HPLC. However, pure ODN 
can be separated from impurities by gravity. So, it does not need high pressure and the 
HPLC instrument. The drawback of this method is that it is highly expensive when doing 
high-throughput purification of ODN due to large column, large volume of harmful 
solvents. Also, the method itself is very slow. 
2.5.5 Affinity Purification 
 Affinity purification is the method that separate ODN from impurities by specific 
interaction. Examples are biotin-avidin affinity purification28 and fluorous 
chromatography.26, 29  
2.5.5.1 Biotin-avidin affinity purification  
 This method utilizes the interaction between biotin and avidin to purify ODN. 
During ODN synthesis, full-length ODN is tagged with biotin while the failure sequences 
are not. Therefore, only full-length ODN will bind with avidin beads in purification 
process. Failure sequences are washed away and pure full-length ODN is obtained from 
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the beads. The problem of this method is that avidin coated beads are very expensive. So, 
large scale purification could be concerned.   
2.5.5.2 Fluorous chromatography 
 The concept of fluorous chromatography is the same as the Biotin-avidin method. 
However, the separation is based on the interaction of fluorous-attached ODN and 
fluorinated absorbent. During automated synthesis, the full-length ODN is tagged with 
fluorousdimethoxytrityl group but the failure sequences are not. Then, crude ODN is 
loaded in the Fluoro-Pak column that contains fluorinated organic groups on polymeric 
resins. Since the full-length ODN (with fluorous tag) has stronger affinity with the 
absorbent than failure sequences, full-length ODN elutes slower and separate from failure 
sequences which elute earlier. Nonetheless, the method has disadvantages. It needs large 
column to scale up the purification which is high cost. In addition, the fluorous column is 
not reusable. 
 
 
 
 
 
 
 
67 
2.6 ODN Characterization 
 After purification, ODN are characterized to confirm its identity. ODN is a large 
and non-volatile molecule. One way to prove the identity of ODN is molecular mass. There 
are two methods used for obtaining molecular mass of ODN. 
2.6.1 Matrixed Assisted Laser Desorption and Ionization Time-of-Flight (MALDI-
TOF) Mass Spectroscopy   
 MALDI-TOF is the technique that can be used to analyze mass of biomolecules.30 
For ODNs, it can determine the molecular mass of sequences up to 50-mer. Sample is 
usually prepared by mixing the ODN and a matrix homogenously (eg.  Dihydroxybenzoic 
acid (DHB), 3-??????????????????????????????-cyano-4-hydroxycinnamic acid (CHCA), 
Picolinic acid, etc.) in organic solvents. The mixture is put on a plate and the solvents are 
evaporated to give dried-droplet spot. The target is loaded into MALDI-TOF machine. 
After that, UV laser irradiates the sample spot. Matrix absorbs UV and transforms it to heat 
energy. Then, matrix heats quickly and leads ODN desorption. The protonized matrix gives 
protons to the ODN. Then, ODN becomes ions (Ionization). Since the energy from the laser 
is not direct to the ODN, the molecular mass can be found in a low fragmentation level. 
After that, the ions are analyzed by Time of flight (TOF) analyzer which determine 
molecular mass of ODN by ion flight time.  
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2.6.2 Electrospray Ionization (ESI) Mass Spectroscopy  
 ESI is suitable for ODN containing up to 150 nucleobases.31 The ODN sample in a 
form of solution is sprayed and ionized to get charged droplets in the electrospray chamber. 
Next, the volatile organic solvent on droplets is desolvated to get ions. Afterward, ions with 
varied charges will travel to detector at different times. Mass to charge ratio of each ion is 
measured by detector. Then, the result will be shown on a mass spectrum. 
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Abstract 
Synthetic oligodeoxynucleotides are purified with use of a catching by 
polymerization, washing, and releasing approach. The method does not require any 
chromatography, and purification is achieved by simple operations such as shaking, 
washing, and extraction. It is therefore useful for large-scale purification of synthetic 
oligonucleotide drugs. In addition to purification of oligonucleotides, this catching by 
polymerization concept is expected to be equally useful for purification of other synthetic 
oligomers such as peptides and oligosaccharides. 
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3.1 Introduction          
 There is a high expectation on using synthetic oligonucleotides (ONs) as 
therapeutics to cure human diseases.1 Currently, one such agent is used clinically and more 
are on various stages of clinical trials. In addition, numerous projects with the goal of 
developing ON drugs through selective gene silencing are in progress. As a result, large 
quantities (kilograms to metric tons) of pure synthetic ONs are needed for preclinical 
research, clinical trials, and patient use.2 Due to the advancement of solid phase synthesis 
technology, large-scale ON synthesis has become possible. However, the crude ON 
contains various impurities, which must be removed for most applications. Current 
purification technologies include trityl-on reverse phase (RP) HPLC, anion exchange 
HPLC, polyacrylamide gel electrophoresis (PAGE), and various types of affinity 
chromatography.3 These methods are either unsuitable or highly expensive for large-scale 
purification, and ON purification has been considered as a bottleneck in antisense drug 
development.2 In this communication, we report the use of an unprecedented concept; 
catching by polymerization; for the development of a simple method for ON purification.4 
This method is easy to perform and uses inexpensive materials, and therefore is suitable 
for large-scale purification. 
 
3.2 Results and Discussion 
The major impurities in crude ON are the failure sequences generated in the 
coupling step in each synthetic cycle. For a typical 20-mer oligodeoxynucleotide (ODN) 
synthesis, the yield of full-length ODN is 40-70% depending on the scale of the synthesis, 
and 30-60% of ODNs are failure sequences.3f During automated synthesis, the failure 
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sequences are capped with acetic anhydride in each synthetic cycle to prevent them from 
coupling with phosphoramidite monomers in the next synthetic cycles. We reasoned that 
if a phosphoramidite that contains a reversibly linked polymerizable function is used in the 
last synthetic cycle, it will ?????????????????????????-end of the full-length ODN. As a result, 
after synthesis, cleavage, and deprotection, all full-length ODN will contain a 
polymerizable group while the failure sequences will not. The full-length sequence can 
then be incorporated into a polymer through a simple copolymerization process, and failure 
sequences and other impurities can be removed by simple washing. Pure ODN can then be 
obtained by cleaving from the polymer. If successful, this purification method does not 
need any chromatography and expensive solid phase affinity extraction materials, and 
purification can be achieved by simple operations such as shaking, washing, and extraction. 
The polymerization reaction we chose for this process was the radical acrylamide 
polymerization reaction. This reaction uses inexpensive materials, and is widely used by 
biologists and biochemists for PAGE. The required phosphoramidite 3.1 that contains the 
polymerizable function (the methacrylamide) and the cleavable linker (the diisopropyl silyl 
acetal) was synthesized using the route shown in Scheme 3.1. The amino tertiary alcohol 
3.3 was prepared by using 3.2 with a known procedure we reported previously.5 This 
compound was acrylated with methacryloyl chloride to give 3.4, which was coupled with 
thymidine by diisopropylsilyl bis(trifluoromethane sulfonate) to give 3.5. Phosphinylation 
of 3.5 with Beaucage’s method provided phosphoramidite 3.1.3a 
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Scheme 3.1. Synthesis of Phosphoramidite 3.1 
 
To prove the purification concept, the 20-mer ODN 3.6 (see Scheme 3.2) was 
synthesized on a 1 ?mol scale with standard phosphoramidite chemistry on CPG on a 
synthesizer. To perform the cleavage and deprotection with ammonium hydroxide at room 
temperature, the UltraMild DNA synthesis conditions were used (see in the experimental 
section).6 In the last synthetic cycle, phosphoramidite 3.1 was used to incorporate the last 
nucleotide and the polymerizable methacrylamide group.  
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The ODN synthesis result was analyzed with RP HPLC (Figure 3.1). The full-
length sequence 3.6 appeared at 57 min due to the hy?????????????????????????-end. Most 
impurities including failure sequences 3.7 have a retention time between 15 and 20 min.  
 
 
 
 
 
 
 
Figure 3.1. RP HPLC profile of crude ODN 
 
For polymerization, the crude ODN (?50 nmol) was dissolved in water. The 
polymerization monomer N,N-dimethylacrylamide and a small amount of cross-linking 
agent N,N?-methylenebis(acrylamide) were added. The polymerization was initiated by 
ammonium persulfate and TMEDA (Scheme 3.2). The reaction is not very sensitive to air 
but it was performed under a nitrogen atmosphere. The polyacrylamide gel 3.8 was formed 
within 30 min at room temperature. To ensure completion of the reaction, the gel was 
allowed to stand for another 30 min. At this stage, the full-length ODN 3.6 was 
incorporated into the polymer 3.8 while impurities including failure sequences 3.7
remained in solution. Water was added to the gel to extract the impurities. The extract was 
analyzed with RP HPLC. As shown in Figure 3.2, the full-length ODN 3.6 was completely 
incorporated into the gel.  
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3.6 Failure sequences
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Scheme 3.2. Purification of ODN with use of the catching by polymerization, washing, 
and releasing approach 
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Figure 3.2. RP HPLC profile of impurities including 3.7 
After drying the gel under vacuum thoroughly, the full-length unmodified ODN 3.9 
was cleaved with HF-pyridine in DMF at room temperature. Excess HF was quenched with 
Me3SiOMe (Scheme 3.2). The supernatant was removed, and the gel was washed with 
water. The supernatant and water were combined. Volatiles, which included Me3SiF, (i-
Pr)2SiF2, MeOH, pyridine, DMF, and water, were evaporated, and the ODN was analyzed 
with RP HPLC. As shown in trace a (Figure 3.3), failure sequences (3.7) and other 
impurities were completely removed, and ODN 3.9 was pure. Due to its lower lipophilicity 
than 3.6, 3.9 has a retention time of 19 min. The recovery yield for the purification process 
was estimated to be 72% by comparing the area of the peak in trace a (Figure 3.3) at 19 
min with the area of the peak in Figure 3.1 at 57 min. This yield is higher than those 
typically obtained with trityl-on and fluorous phase purification methods. We anticipated 
that the yield of this new technology could be further increased when the process is used 
for larger scale ODN purification. By comparing Figure 3.1, 3.2, and 3.3, we can also 
conclude that the diisopropyl silyl acetal linker is stable during ODN synthesis, cleave, 
deprotection, acrylamide gel formation, and extraction of failure sequences.  
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Figure 3.3. RP HPLC profile of ODN 3.9 purified by polymerization, washing, and 
releasing 
 
The identity of ODN 3.9 was established by comparing with an authentic sample 
synthesized under standard conditions and purified with RP HPLC by a company (Figure 
3.4, trace b). As shown in Figure 3.3 (trace a), a co-injection of 3.9 purified by using our 
technology with an authentic sample gave a single peak. The HPLC profile for the authentic 
sample is shown in trace b of Figure 3.4. MALDI-TOF analysis of 3.9 also gave correct 
molecular weight. Because damaged ODNs resulting from nucleobase modifications under 
radical polymerization conditions may not be able to be detected by HPLC and MALDI-
TOF, the four nucleosides, adenosine, thymidine, guanosine, and cytidine, were subjected 
to the polymerization conditions, and then recovered from the polyacrylamide gel by 
extraction. HPLC analysis showed that these compounds are completely stable under the 
polymerization conditions (see in the experimental section). 
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 Figure 3.4. RP HPLC profiles: (a) co-injection of ODN 3.9 and control ODN; (b) control 
ODN  
 
This new ON purification technology has significant advantages over known ones. 
The most widely used method for ON purification is trityl-on RP HPLC. Compared with 
this method and other methods that use more hydrophobic tags than DMTr,3e our technique 
does not need any capital expenses including those for the highly expensive and 
consumable preparative columns. In addition, our technique only needs a minimum amount 
of organic solvents. The polymerization, removing failure sequences, and extraction of 
full-length ON are all carried out with water as the solvent. Furthermore, our method is 
expected to give better results for purification of ONs that are prone to adopt secondary 
structures and phosphorothioates that contain different diastereoisomers. These materials 
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usually gave broad peaks in chromatography.7 In the literature, ONs have also been purified 
with fluorous affinity chromatography3f,g and biotin-avidin enabled affinity extraction.3b-d 
Compared with these methods, our technique does not need any expensive affinity 
materials such as fluorous affinity column and avidin coated beads. ON purification 
methods involving capping failure sequences with reagents that contain reactive groups 
such as a diene were also proposed.8 Using these methods, failure sequences could be 
removed by extraction with dienophile functionalized microspheres through a Diels-Alder 
reaction. Compared with these methods, our technology does not need any reactive group 
functionalized microspheres, which could be highly expensive. In addition, due to the 
intrinsically lower reaction rate of heterogeneous reactions than homogeneous reactions, 
and the fact that only groups on the surface of solids can participate in reactions and the 
majority of groups within the solids cannot, to efficiently remove failure sequences, the 
previously proposed methods require a large excess of solid phase extraction materials, 
which will prevent them from being used for large-scale ON purification. In contrast, our 
technology does not rely on any heterogeneous reactions for purification. In principle, the 
ratio of the polymerization monomer over ON can be kept to a minimum as long as the 
steric bulkiness of ON does not significantly slow down the polymerization.  
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3.3 Conclusion 
We have developed a new method for the purification of synthetic ON. This method 
is based on an unprecedented concept, which is catching by polymerization.4 With use of 
this method, purification was achieved by simple operations such as shaking, washing, and 
extraction; and the method does not require any expensive equipment and materials. As a 
result, it is suitable for large-scale purification. Application of this new concept for the 
purification of other synthetic oligomers such as RNA,3b modified ON, peptides,9 and 
oligosaccharides10 is in progress. 
 
3.4 Experimental Section 
General Experimental 
All reactions were performed in oven-dried glassware under a nitrogen atmosphere 
using standard Schlenk techniques. Reagents and solvents available from commercial 
sources were used as received unless otherwise noted. Toluene, benzene and THF were 
distilled from Na/benzophenone ketyl. 1,2-dichloroethane, 1,4-dioxane, CH2Cl2 and 
pyridine were distilled over CaH2. Thin layer chromatography (TLC) was performed using 
Sigma-Aldrich TLC plates, silica gel 60F-254 over glass support, 0.25 μm thickness. Flash 
column chromatography was performed using Selecto Scientific silica gel, particle size 32-
63 μm. Melting points were determined using a MEL-TEMP® melting point apparatus and 
are uncorrected. GC-MS were measured on GCMS-QP5050A, Shimadzu; column, DB-
5MS, 0.25 μm thickness, 0.25 mm diameter, 25 m length; MS, positive EI.1H, 13C and 31P 
NMR spectra were measured on a Varian UNITY INOVA spectrometer at 400, 100 and 
162 MHz, respectively; chemical shifts (?) were reported in reference to solvent peaks 
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(residue CHCl3 at ?7.24 ppm for 1H and CDCl3 at ?77.00 ppm for 13C; residue CHD2OD 
at ?3.31 ppm for 1H and CD3OD at  ?49.00 ppm for 13C) and H3PO4 (at ?0.00 ppm for 31P). 
High-resolution mass spectra were obtained on a Finnigan Mat 95XL spectrometer. 
MALDI-TOF mass spectra were obtained on a Shimadzu Biotech Axima CFRplus 
spectrometer. ODNs were synthesized on an ABI 394 solid phase synthesizer. HPLC was 
performed on a JASCO LC-2000Plus System, Pump PU-2089Plus Quaternary Gradient 
Pump, Detector UV-2075Plus. C-18 reverse phase analytical column (100Å, 250 3 4.6 
mm). Solvent A: 0.1 M triethylammonium acetate, 5% acetonitrile; solvent B: 90% 
acetonitrile; all profiles were generated by detection of absorbance of DNA at 260 nm using 
the linear gradient solvent system: solvent B (0-45%) in solvent A over 60 min at a flow 
rate of 0.5 mL/min. Aqueous NH4OH (~29%), HF-pyridine (HF,~70%; pyridine, ~30%) 
and Me3SiOMe were purchased from Aldrich Inc. THF/pyridine/Pac2O, succinic ester 
linked DMTr-dT-lcaa-CPG (pore size 1000 Å ) and 5´-DMTr, 2-
cyanoethylphosphoramidites acetyl-dC, Pac-dA, 4-isopropyl-Pac-dG and dT were 
purchased from Glen Research, Inc.  
 
Synthesis of compound 3.2. 
OO
O
OO
1. EtMgBr (2 equivalents), THF
2. AcOH
3.2Succinic anhydride  
Succinic anhydride (15.0 g, 150 mmol, 1.0 eq.) was added in a round bottomed 
flask, and the flask was flushed with nitrogen. THF (500 mL) was added via syringe. The 
solution was cooled to 0 °C. Methyl magnesium bromide in ether (3.0 M, 100 mL, 300 
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mmol, 2.0 eq.) was added via syringe slowly. The reaction mixture was warmed to rt 
gradually, and then heated to 50 °C for 12 h. A yellow solution was formed. After cooling 
the reaction mixture to rt, AcOH was added until pH = 4, and stirring was continued for an 
additional 12 h. Water (75 mL) was added, and THF and ether were removed under reduced 
pressure. The green suspension was extracted with CH2Cl2 (60 mL × 5), and the organic 
phase was dried over anhydrous Na2SO4 and concentrated. Purification by vacuum 
distillation gave 3.2 (9.7 g, 46%) as brown oil. This compound has been synthesized using 
several different methods in the literature.11-13 
 
Synthesis of compound 3.3. 
OO
HN
NH2
OH
10
O
3.3
1,12-diaminododecane
H2O, reflux
3.2  
A procedure reported previously by us was followed.3c,5 Compound 3.2 (2.7 g, 19.1 
mmol, 1.0 eq.), 1,12- diaminododecane (9.6 g, 47.7 mmol, 2.5 eq.), and water (8.0 mL) 
were combined. The solution was refluxed under a nitrogen atmosphere overnight. A 
yellow solution was formed. After cooling to rt, water was removed under reduced 
pressure. The yellow oily residue was purified by flash column chromatography (SiO2, 
Et2O/CH3OH/CH3CN/Et3N = 5 : 2 : 2 :1) to give 3.3 as a light yellow solid (2.0 g, 30%). 
Rf = 0.5 (Et2O/CH3OH/CH3CN/Et3N = 5 : 2 : 2 : 1);  1H NMR (400 MHz,CDCl3) ??5.67 
(br s, 1H), 3.23-3.18 (m, 2H), 2.67 (t, 2H, J = 7.2 Hz), 2.25 (t, 2H, J = 7.2 Hz), 2.02 (br s, 
3H), 1.74 (t, 2H, J = 7.2 Hz), 1.50-1.40 (m, 8H), 1.33-1.20 (m, 16H), 0.85 (t, 6H, J = 7.2 
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Hz); 13C NMR (100 MHz, CDCl3) ? 174.2, 73.9, 42.2, 39.9, 33.7, 31.0, 30.9, 29.7, 29.6, 
29.7, 29.4, 27.1, 27.0, 8.1; HRMS (ESI, [M + H]+) m/z calculated for C20H42N2O2 343.3325, 
found 343.3321. 
 
Synthesis of compound 3.4. 
HN
NH2
OH
10
O Methacryloyl chloride
DIEA, 0oC, 12 h
86 %
N
H
O
N
H
O
10
OH
3.3 3.4  
To a round bottom flask under a nitrogen atmosphere was added 
diisopropylethylamine (750 μL, 4.31 mmol, 2.5 eq.), 3.3 (0.6 g, 1.75 mmol, 1.0 eq.), and 
CH2Cl2 (120 mL). The solution was cooled to 0 °C. Methacrolyl chloride (171 μL, 1.75 
mmol, 1.0 eq.) was added via a syringe. The flask was then detached from the nitrogen 
atmosphere and connected to air via a Drierite tube. The reaction mixture was stirred at rt 
overnight. The content were then transferred into a separation funnel, and were washed 
with water (50 mL), which was extracted with CH2Cl2 (50 mL × 2). The combined organic 
phase was dried over anhydrous Na2SO4. Volatiles were then removed under reduced 
pressure. The crude product was purified by flash column chromatography (SiO2, 
CH2Cl2/CH3OH = 97 : 3) giving 3.4 as a white solid (0.6 g, 86 %). Rf = 0.7 (CH2Cl2/ 
CH3OH = 9 : 1); 1H NMR (400 MHz,CDCl3) ??5.85 (br s, 2H), 5.63-5.62 (m, 1H), 5.28-
5.27 (m, 1H), 3.26 (dt, 2H, J = 8.4, 6.0 Hz), 3.18 (dt, 2H, J = 6.8, 6.0 Hz), 2.52 (br s, 1H), 
2.25 (t, 2H, J = 7.2 Hz), 1.93 (dd, 3H, J = 1.2, 0.8 Hz), 1.73 (t, 2H, J = 7.2 Hz), 1.52-1.41 
(m, 8H), 1.31-1.20 (m, 16H), 0.83 (t, 6H, J = 7.6 Hz); 13C NMR (100 MHz, CDCl3) ? 
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174.2, 168.6, 140.5, 119.3, 73.9, 39.9, 33.6, 31.1, 30.9, 29.7, 29.6, 29.4, 27.1, 18.9, 8.1; 
HRMS (ESI, [M + H]+) m/z calculated for C24H46N2O3 411.3587, found 411.3582. 
 
Synthesis of compound 3.5. 
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(TfO)2Si(i-Pr)2, DIEA
DMF, 0oC, 3h
then thymidine
0oC, 3 h 3.5  
Compound 3.4 (274 mg, 1.0 mmol, 1.0 eq) in a 2-necked round bottomed flask was 
dried under vacuum. The flask was then refilled with nitrogen. The vacuum-nitrogen cycle 
was repeated for two additional times. Dry DMF (5 mL) and diisopropylethylamine (350 
μL, 3.0 mmol, 3.0 eq) were added via a syringes. After cooling to 0°C, diisopropyl silyl 
bis(trifluoromethane sulfonate) (196  μL, 1.0 mmol, 1.0 eq) was added via a syringe in one 
portion. The solution was stirred at 0°C for 1 h and rt for 2 h. The reaction mixture was 
then cooled to 0°C again. A solution of thymidine (162 mg, 1.0 mmol, 1.0 eq) in dry DMF 
(1.5 mL) were added via a cannula. After stirring at 0°C for 3 h, DMF was removed under 
vacuum. To the residue, ice-cooled EtOAc (60 mL) and NaHCO3 solution (5%, 50 mL) 
were added, and the phases separated. The aqueous phase was further extracted with ice-
cooled EtOAc (0°C, 50 mL × 4). The organic phase was dried over anhydrous Na2SO4. 
EtOAc was removed under reduced pressure to give the crude product as a yellow oil, 
which was purified by flash column chromatography (SiO2, CH2Cl2/CH3OH from 100 : 0 
to 95 : 5) giving 3.5 as a white foam (370 mg, 73 %). Rf = 0.6 (CH2Cl2/ CH3OH = 9 : 1,);  
1H NMR (400 MHz, CD3OD) ?  7.92 (br s, 1H), 7.82 (br t, 1H, J = 5.2 Hz), 7.49 (s, 1H), 
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6.24 (dd, 1H, J = 7.2, 3.2 Hz), 5.64 (s, 1H), 5.32 (s, 1H), 4.42 (dt, 1H, J = 6.4, 2.8 Hz), 
4.02-3.91 (m, 3H), 3.24-3.16 (m, 2H), 3.16-3.09 (m, 2H),  2.29-2.13 (m, 4H), 1.91 (dd, 3H, 
J = 1.6, 0.8 Hz), 1.86 (d, 3H, J = 1.2 Hz), 1.86-1.81 (m, 2H), 1.66-1.40 (m, 8H), 1.36-1.24 
(m, 16H), 1.12-1.00 (m, 14H), 0.90 (t, 6H, J = 7.2 Hz); 13C NMR (100 MHz, CD3OD) ? 
174.6, 170.0, 165.0, 151.0, 140.3, 136.2, 118.9, 110.3, 87.3, 84.8, 79.0, 70.7, 62.9, 39.8, 
39.5, 39.2, 34.7, 31.61, 31.57, 30.7, 29.5, 29.3, 26.8, 17.7, 17.42, 17.36, 17.32, 17.29, 13.8, 
13.7, 11.5, 7.7; HRMS (ESI, [M+H]+) calculated for C40H72N4O8Si 765.5198, found 
765.5186. 
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A round-bottomed flask containing 3.5 (150 mg, 0.20 mmol, 1.0 eq.) was flushed 
with nitrogen. Dry CH2Cl2 (6 mL) and 2-cyanoethyl- N,N,N´,N´- tetraisopropyl 
phosphoramidite (68 μL, 0.22 mmol, 1.1 eq.) were added via a syringe sequentially. To the 
resulting solution was added the solution of 1H-tetrazole in CH3CN (0.45 M, 480 μL, 0.22 
mmol, 1.1 eq.) in three portions over a period of 1 h. After stirring at rt for another 2 h, the 
reaction mixture was concentrated under reduced pressure. The residue was purified by 
flash chromatography (hexanes/CH2Cl2/Et3N = 1 : 2 : 0.3), giving 3.1 as a white foam (158 
mg, 84%). Rf = 0.5 (hexanes/CH2Cl2/Et3N = 1 : 2 : 0.3); 1H NMR (400 MHz, CDCl3) ? 
92 
7.37 (s, 0.7H), 7.32 (s, 0.3H), 6.29 (dd, 1H, J = 8.0, 6.4 Hz), 5.63 (s, 1H), 5.27 (q, 1H, J = 
1.2 Hz), 4.61-4.52 (m, 1H), 4.18-3.52 (m, 7H), 3.32-3.21 (m, 2H), 3.21-3.10 (m, 2H), 2.67-
2.56 (m, 2H), 2.50-2.34 (m, 1H), 2.24-2.14 (m, 2H), 2.13-2.02 (m, 1H), 1.95-1.91 (m, 3H), 
1.87 (s,3H), 1.87-1.79 (m, 2H), 1.64-1.38 (m, 8H), 1.30-1.10 (m, 28H), 1.10-0.95 (m, 14H), 
0.85 (t, 6H, J = 7.2 Hz); 13C NMR (100 MHz, CDCl3) ? 173.1, 168.6, 163.8, 150.4, 140.5, 
135.5, 119.2, 117.8, 111.2,  86.7, 86.3 (d, J = 6.1 Hz), 84.8, 84.6, 79.3, 73.6 (d, J = 18.3 
Hz), 62.8, 58.3 (d, J = 18.0 Hz), 43.5 (d, J = 12.2 Hz), 39.9, 39.7, 34.7, 34.6, 32.0, 31.9, 
31.2, 29.8, 29.75, 29.67, 29.46, 29.43,  27.1, 24.84, 24.77, 24.74, 24.6,  20.6, 18.9, 18.29, 
18.26,18.13, 18.06, 14.1, 14.0, 13.7, 12.5, 8.7; 31P NMR (160 MHz, CDCl3) ??150.1, 149.8 
 
Synthesis of ODN 3.6  
N
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O OH
TCGCCAGATTCGTCGTTACHO
3' 5'
3.6  
ODN 3.6 was synthesized on an ABI 394 solid phase synthesizer using standard 
phosphoramidite chemistry under UltraMild conditions on controlled pore glass (CPG, 
pore size 1000 Å) on a 1 μmol scale. The succinyl ester linkage was used to anchor the ON 
to CPG. The phosphoramidite monomers used were Pac-dA-CE, Ac-dC-CE, i-Pr-Pac-dG-
CE and dT-CE. Manufacture recommended synthetic cycles were adopted. In the last 
synthetic cycle, phosphoramidite 3.1 (in acetonitrile, 0.1 M, which is two times of normal 
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phosphoramidite concentration) was coupled to 5´-end of the ON for 5 min. Detritylation 
was not performed in the last synthetic cycle. Cleavage and deprotection were carried out 
on the synthesizer with concentrated NH4OH (900 min × 4) at rt. The solution was 
distributed equally into 20 Eppendorf tubes (1.5 mL), and dried in a SpeedVac, separately 
(each portion contained ~50 nmol ON, P1-P20). P1 was dissolved in 80 μL water, 20 μL 
(~12.5 nmol) was injected into RP HPLC to generate the profile (Figure 3.1).  
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The crude ON 3.6 (P2) was transferred into a 25 mL 2-necked round bottomed flask 
by dissolving into water (100 μL, 50 μL × 3). To the flask was also added aqueous 
dimethylacrylamide solution (250 μL; N,N-dimethylacrylamide 1.69 M, N,N´-
methylenebis(acrylamide) 16.9 mM; the solution could be stored at -????????????????????
month). The flask was flushed with nitrogen for 2 min with gentle stirring. (NH4)S2O8 
(10%, 5 μL) and N,N,N´,N´-tetramethylethylenediamine (TMEDA, 5 μL) were added 
sequentially via pipettes under positive nitrogen pressure. The solution was stirred gently 
under nitrogen at rt. A gel, which was the ON-polyacrylamide conjugate 3.8, was formed 
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within 30 min, which was allowed to stand for another 30 min to ensure completion of 
polymerization (Scheme 3.2). 
 
?????????????????????????????????????3.7 and other impurities 
The gel 3.8 in the 2-necked round bottomed flask was broken into smaller pieces 
with a glass rod. Water (5 mL) was added via a pipette. The content was gently stirred 
overnight (gentle shaking may be better) at rt. The supernatant, which contains failure 
sequences 3.7 and other impurities, was removed using a pipette (on large scale, filtration 
should be more convenient). To analyze the efficiency of the catching by polymerization 
process, the supernatant was concentrated to ~1 mL and desalted using a D-Salt™ dextran 
desalting column (5K MWCO). After concentration to dryness in a SpeedVac concentrator, 
80 μL water was added, 20 μL was injected into RP HPLC to generate the profile (Figure 
3.2). The gel was further rinsed with water (3 mL/1 h × 3) to ensure complete removal of 
impurities.  
 
??????????????????????????-length ODN 3.9 from polymer 
3´ HO-TCGCCAGATTCGTCGTTAC-OH 5´ (3.9)  
The gel was transferred into a 1.5 mL Eppendorf tube and dried under vacuum 
overnight. To the tube was added dry DMF (1 mL) and HF-??????????????????????????? ???
vortexed shortly, and then was allowed to stand for 5 h at rt. At this stage, ODN 3.9 was 
cleaved from polymer (Scheme 3.2). The supernatant was transferred into another 
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Eppendorf tube. To the gel was added Me3???????????????? ??????????????????????????? ????
Me3SiOMe was combined with the supernatant, and mixture was stand at rt for a minimum 
of 15 min. The gel was transferred into a round bottomed flask and water (5 mL) was 
added. The mixture was stirred gently at rt for 12 h. The supernatant was removed via a 
pipette. The gel was further extracted with water (3 mL/2 h × 2). All supernatants (DMF, 
Me3SiOMe and water) were combined and dried to dryness. The residue was dissolved in 
?????????????????????????????????????????????????????????the profile in Figure 3.3. The 
recover yield for the purification process was estimated to be 72% by comparing the area 
of the peak in Figure 3.3 at 19 min with the area of the peak in Figure 3.1 at 57 min. 
 
Identification of ODN 3.9 
The authentic ODN of 3.9 was synthesized using standard phosphoramidite 
????????????????????????????????????????? ??????????-on RP HPLC at The Midland Certified 
Reagent Company, 
Inc. (Midland, TX, USA). MALDI-TOF spectrum of the authentic ODN was also obtained 
at the company showing correct molecular weight: calculated for [M – H]? 6057, found 
6060. At Michigan Tech, the authentic sample was divided equally into 20 portions (each 
portion contains ~50 nmol ODN assuming the yield for the synthesis and purification was 
????????????????????????????????????????????????????????????????????????????????????
generate trace b (Figure 3.4). To compare ODN 3.9 synthesized in our lab and purified 
using our catching by polymerization, washing and releasing technique with the authentic 
?????????????????????????????????????????????????????in Figure 3.3 ??????????????????????????
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used to generate trace b in Figure 3.4 were mixed, and injected into RP HPLC to generate 
trace a (Figure 3.4). A single peak was observed showing the two were identical. ODN 3.9 
was also characterized with MALDI-TOF: calculated for [M – H]? 6057, found: 6057. In 
addition, two other peaks were also observed in the mass spectrum: calculated for [M – 2H 
– adenine]? 5922, found: 5925; and calculated for [M – 2H]2? 3028, found: 3030.14 The 
spectrum is attached in the MALDI-TOF mass spectrum of ODN 3.9 purified using the 
catching by polymerization, washing and releasing approach section of appendix A. 
 
Testing the stability of nucleobases under radical acrylamide polymerization 
conditions 
5 mg of guanosine (dG) was charged into a 2-necked round bottomed flask. Water 
??????????????????????????????????????????????????????????????????????????????????????
gentle heating with a heat gun, a solution was formed. After cooling to rt, 
??????????????????? ????????? ????? ???? N,N-dimethylacrylamide 1.69 M, N,N´-
methylenebis(acrylamide) 16.9 mM] was added. The flask was flushed with nitrogen for 
~3 min. (NH4)2S2O8 solution (10?????????????????????????? ??????????????????? ???????
was gently stirred at rt. The polymerization was allowed to proceed for 1 h. Water (5 mL) 
was added to extract dG (rt, 3 h, gentle stirring). The extract was removed. The gel was 
further extracted with DMF (rt, 6 h, gentle stirring, 2 mL × 2). All extracts were combined 
and evaporated to dryness in a SpeedVac concentrator. The residue was dissolved in 15 
????????????????????????????????????????????????????????????????????????????????general 
experimental section were used) to generate HPLC profile Recovered dG (Figure 3.5). 
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Figure 3.5. HPLC profile of recovered guanosine 
The authentic dG (2.5 mg) ????????????????????????????????????????????????????
into HPLC to generate HPLC profile Authentic dG (Figure 3.6).  
Figure 3.6. HPLC profile of authentic guanosine 
 
Commercially available 8-oxo-guanosine (1 mg) was dissolved in 8 mL buffer A, 
?????? ?????????????????? ???????????????? ????????????Authentic 8-oxo-dG (Figure 3.7).
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Figure 3.7. HPLC profile of authentic 8-oxo-guanosine 
 
The co-injection HPLC profile of recovered guanosine and authentic guanosine was 
?????????????????????????????????????????????????????????????????????????????????????????
they are identical (Figure 3.8).  
 
 
 
 
 
 
 
Figure 3.8. Co-injection HPLC profile of recovered guanosine and authentic guanosine  
 
The co-injection HPLC profile of recovered guanosine and authentic 8-oxo-
guanosine ??????????????????????????????????????????????????????????????????????????
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which indicated that the recovered guanosine was not oxidized to 8-oxo-guanosine (Figure 
3.9).  
Figure 3.9. Co-injection HPLC profile of recovered guanosine and authentic 8-oxo-
guanosine  
The other three nucleosides, adenosine (dA), thymidine (dT) and cytidine (dC), are 
more soluble in water, and the procedures for testing their stability under radical conditions 
were slightly different from that for dG. The one for dA is described. Adenosine (5.0 mg) 
was charged into a 2-necked round bottomed flask. A solution was formed after stirring 
with gentle heating with heat gun. To the solution, a dimethylacrylamide s?????????????????
N,N-dimethylacrylamide 1.69 M, N,N´- methylenebis(acrylamide) 16.9 mM] was added. 
The flask was flushed with nitrogen for ~3 min. (NH4)2S2O8 ????????? ???????????? ????
?????????????????????????????????????????????????????????????????????????lymerization 
was allowed to proceed for 1 h. Water (2 mL) was added to extract dA (rt, 12 h, gentle 
stirring). The extract was removed. The gel was further extracted with water (rt, 3 h, gentle 
stirring, 2 mL × 2). All extracts were combined and evaporated to dryness in a SpeedVac 
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(eluting conditions described in the general experimental section were used) to generate 
HPLC profile Recovered dA (Figure 3.10). A single peak was observed. 
Figure 3.10. HPLC profile of recovered adenosine 
 
?????????????????????? ??? ??????????????????? ?? ????????????????????????? into 
HPLC to generate HPLC profile Authentic dA (Figure 3.11).  
Figure 3.11. HPLC profile of authentic adenosine 
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The co-injection HPLC profile Recovered dA + Authentic dA (Figure 3.12) was 
?????????????????????????????????????????????????????????????????????????????????????????
they are identical.  
 
 
 
 
 
 
 
Figure 3.12. Co-injection HPLC profile of recovered adenosine and authentic adenosine 
The nucleosides thymidine (dT) and cytidine (dC) were subjected into the same 
radical polymerization conditions, respectively. The recovered nucleosides were dissolved 
?????????????????????????????????????????????to generate profiles Recovered dT (Figure 
3.13) and Recovered dC (Figure 3.14), respectively.  
 
 
 
 
 
 
Figure 3.13. HPLC profile of recovered thymidine 
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Figure 3.14. HPLC profile of recovered cytidine 
 
The authentic dT (5.0 mg) and authentic dC (5.0 mg) were dissolved in 5 mL water, 
??? ??? ????? ????????? ????? ????? ??? ????????? ????????? Authentic dT (Figure 3.15) and 
Authentic dC (Figure 3.16), respectively.  
 
 
 
 
 
 
Figure 3.15. HPLC profile of authentic thymidine 
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Figure 3.16. HPLC profile of authentic cytidine 
The co-injection HPLC profiles Recovered dT + Authentic dT (Figure 3.17) and 
Recovered dC + Authentic dC (Figure 3.18) ?????????????????????????????????????????????
Single peaks were observed, which indicated that the nucleosides were stable under the 
radical polymerization conditions. 
 
 
 
 
 
 
 
Figure 3.17. Co-injection HPLC profile of recovered thymidine and authentic thymidine 
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Figure 3.18. Co-injection HPLC profile of recovered cytidine and authentic cytidine 
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Abstract 
Synthetic oligodeoxynucleotide is purified by capping failure sequences with an 
acrylated phosphoramidite followed by polymerization and product extraction. The method 
is suitable for large scale oligonucleotide drug purification. 
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4.1 Introduction 
For most applications of synthetic oligonucleotides (ONs) such as in PCR, only 
submicromolar quantities are needed. These amounts of ONs can be synthesized using 
automated solid phase synthesis and purified with polyacrylamide gel electrophoresis or 
HPLC with reasonable costs.1 In recent years, recognition of the ability of ONs to 
selectively silence gene expression, and thus potentially treat a wide range of human 
diseases, demands quantities of pure ONs at the kilogram to metric ton scales.2 Synthesis 
at this level is now possible using solid phase synthesis and phosphoramiditechemistry.3 
Besides the desired full-length sequence, the crude ON contains impurities, which include 
truncated failure sequences generated in each synthetic cycle due to incomplete coupling, 
small molecules resulting from protecting groups, and minute quantities of deletion 
sequences from incomplete detritylation and incomplete capping, and addition sequences 
from premature detritylation before and during coupling.  
For a typical synthesis of a 20-mer oligodeoxynucleotide (ODN) on a controlled 
pore glass (CPG), the failure sequences constitute 30–60% of the total ODN content 
depending on the scale of synthesis.4 Because these impurities have the same physical 
properties as the full-length ODN, they are difficult to remove. The most powerful 
polyacrylamide gel electrophoresis (PAGE) can efficiently separate them, but this method 
cannot be scaled up. HPLC methods, especially trityl-on reverse phase (RP) and anion 
exchange HPLC, have been adapted to purify large scale ONs, which removes impurities 
including failure sequences.5 However, these methods require expensive instrument and 
preparative column. In addition, large volumes of solvent are needed, which must be 
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subsequently evaporated. As a result, the method is very expensive for large scale 
purification. 
Several other methods have also been developed for the removal of failure sequences 
including biotin–avidin enabled affinity extraction,6 fluorous affinity extraction,4,7 
hydrophobic RP chromatography,8 and reaction-based solid phase extraction.9 All these 
methods are still expensive for large scale purification as we discussed in a previous 
paper.10  
Unlike the removal of failure sequences, the separation of small molecule 
contaminants can be easily achieved by known methods such as simple n-BuOH 
precipitation.11 Other ON-based impurities such as deletion and addition sequences are the 
most challenging to remove. Fortunately, they only exist in minute quantities. For large 
scale ON drug production, the best option is to adjust synthesis conditions to keep them at 
an acceptable level.  
 
4.2 Results and Discussion 
For separation of full-length ODN from failure sequences, we recently reported a 
method involving using a reversibly acrylated phosphoramidite to couple to the 50-end of 
full-length sequence. Because the failure sequences were all capped with Ac2O, only full-
length sequence had a polymerizable acrylamide group. The crude ODN was subjected to 
polymerization. The full-sequence was incorporated into a polymer, and the failure 
sequences were removed by washing. Cleaving the full-length ODN from the polymer gave 
a pure product.10 In this communication, we report an even more convenient method for 
ODN purification, which involves capping failure sequences with an acrylated 
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phosphoramidite and incorporating them into a polymer. Using this method, full-length 
ODN can be simply extracted with water.  
The acrylated phosphoramidite 4.1 (Figure 4.1) for this application was synthesized 
in two steps from 6-amino-1-hexanol with only one flash column chromatography 
purification. To prove the new purification concept, the 20-mer 4.4 (0.2 mmol) was 
synthesized on CPG on a standard synthesizer. In the synthetic cycle (see appendix B), the 
steps for Ac2O capping in a standard cycle were removed. Instead, capping was achieved 
in added steps using a 0.2 M acetonitrile solution of 4.1. This solution was placed on the 
synthesizer in a bottle typically employed for additional phosphoramidites besides the ones 
for natural nucleotides. The tetrazole solution (0.45 M) used to activate 4.1 was from the 
same bottle used for the coupling steps. To ensure complete capping, 4.1 and the activator 
were delivered to the synthesis column four times instead of two times normally used in 
coupling. Because the failure sequences may locate at sites difficult for reagents to reach 
in CPG, the oxidation of the newly formed phosphitetriesters was carried out three times. 
In the last cycle, detritylation was performed. Cleavage and deprotection were carried out 
with concentrated NH4OH.  
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Figure 4.1. Structure of capping phosphoramidite 4.1 
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The crude ODN was analyzed with RP HPLC. As shown in Figure 4.2, the full-
length sequence appeared at ~19 min. Normally, when Ac2O is used for capping, failure 
sequences have a shorter retention time than the full-length sequence. Here, due to the 
relatively more hydrophobic tag on 4.5, the order is reversed; and the failure sequences 
appeared at ~20 minutes. The small peaks at around 10, 28, and 56 min were probably due 
to small molecules from protecting groups. The tiny peaks, which could be hardly seen in 
a at the left of the full-length ODN, might be resulted from un-capped failure sequences, 
deletion sequences, or damaged sequences.12 According to our experience, from the 
relative intensity of peaks of the full-length ODN and the failure sequences, the 
modification of the synthetic cycle did not affect the efficiency of ODN synthesis.  
 
Figure 4.2. HPLC profile of crude ODN 
The purification process is shown in Scheme 4.1. The crude ODN (~50 nmol), 
which mainly contains the full-length sequence 4.4, failure sequences 4.5, and small 
molecules (not shown), was dissolved in 250 mL water. A solution of N,N-
dimethylacrylamide and N,N´-methylenebis(acrylamide) (250 mL) were added. The 
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polymerization was initiated with (NH4)2S2O8 and TMEDA, and allowed to proceed at rt 
for 1 h. The failure sequences 4.5 were incorporated into polymer 4.6. The full-length 4.4 
and small molecules remained in the polymer matrix. Water was then added; and 4.4 and 
small molecules were extracted. The extract was analyzed with HPLC (Figure 4.3). To our 
surprise, four peaks instead of one at ~19 min appeared besides the weaker peaks from 
small molecules. 
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Scheme 4.1. Purification of ODN by polymerization of failure sequences 
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Figure 4.3. HPLC profile of pure ODN after polymerization 
From our previous studies,10 we knew that ODN is stable under the radical 
polymerization conditions. We repeated the experiments for three times, and the HPLC 
profiles from all trials were identical. One possibility is that the nucleophilic sites of the 
full-length ODN reacted with acrylamide during polymerization through conjugate 
addition.13 If this is true, the adduct should not be stable and the reaction may be reversed 
to give unmodified ODN. Based on this hypothesis, the experiment was continued as 
planned. The extract was passed through a D-Salt dextran column (5 K MWCO), and 
analyzed with HPLC (Figure 4.4, trace a). As expected, the small molecules were removed. 
In addition, the four ODN peaks at ~19 min merged into three, which indeed supported our 
hypothesis of conjugate addition. To completely reverse the reaction, the ODN was heated 
in concentrated NH4OH at 80 ºC for 15 min,14 and analyzed with HPLC. As shown in trace 
b (Figure 4.4), the remaining three peaks merged into one, and the ODN was pure.  
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Figure 4.4. RP HPLC profiles of pure ODN 4.4 after (a) polymerization and desalting, 
(b) polymerization, desalting, and treating with NH4OH  
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The identity of 4.4 was confirmed by co-injection with authentic sample. As shown 
in trace a (Figure 4.5), a single peak was observed. The trace for control (Figure 4.5, trace 
b) is also shown. MALDI-TOF analysis of 4.4 gave the correct molecular weight. The 
recovery yield of the purification process was determined to be 83% by comparing the area 
of the peak in trace b of Figure 4.4 with the peak area in Figure 4.2 at ~19 min.  
Figure 4.5. RP HPLC profiles of (a) co-injection of ODN 4.4 with control, (b) control 
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There are several known methods for removing small molecules from ODN 
including size exclusion chromatography, dialysis, and EtOH, 2-PrOH or n-BuOH 
precipitation.11 Size exclusion chromatography, which we used in our initial studies, is easy 
to perform on small scales, but expensive on large scales. The n-BuOH precipitation 
method is simple, has high recovery yield, and can be easily scaled up. Therefore, we 
repeated the entire purification process including polymerization, extraction, and treating 
with concentrated NH4OH. However, size exclusion chromatography was omitted. Instead, 
after treating with concentrated NH4OH, n-BuOH was added. The ODN precipitated, while 
the small molecules remained in the supernatant. HPLC analysis showed that the ODN was 
pure (Figure 4.6).15 The recovery yield of the procedure was determined to be 85% by
comparing the peak area in Figure 4.6 with the peak area in Figure 4.2 at ~19 min.  
 
 
 
 
 
 
 
Figure 4.6. RP HPLC profiles of ODN 4.4 after polymerization, NH4OH, and n-BuOH 
precipitation 
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Phosphoramidite 4.1 is stable under nitrogen at ~20 ºC for at least three weeks. We 
also put its 0.2 M acetonitrile solution on DNA synthesizer for one week, no reduction of 
the capping efficiency was observed. Based on this information, 4.1 or its modified version 
could be made commercially available. Once this is realized, ODN purification, on large 
and small scales, can be simply achieved through the following steps: (1) synthesize ODN 
on a standard synthesizer using 4.1 as the capping agent. (2) Add reagents to polymerize 
failure sequences. (3) Extract full-length sequence by water. (4) Treat with concentrated 
NH4OH briefly. (5) Add n-BuOH to precipitate pure ODN. This purification method does 
not need any chromatography, which requires expensive instrument and large volumes of 
solvent (solvent to ODN mass ratio can be as high as 105). Instead, purification is achieved 
by simple operations such as shaking and extraction. Using this method, the waste to 
product mass ratio (defined as the weight of polymerization reagents divided by that of 
ODN) in the purification procedure can be less than 102. As a result, the method is suitable 
for large scale ODN drug purification.  
 The current ODN purification method and the method we reported earlier 
complement each other. In the earlier method,10 purification is achieved by polymerization 
of full-length sequence followed by washing, cleavage and extraction. That method only 
requires the polymerizable phosphoramidite in the last synthetic cycle, and the failure 
sequences are capped with less expensive Ac2O. In addition, impurities such as the small 
molecules from protecting groups can also be removed in the washing step. Therefore that 
method is suitable for purification of long ODN (longer than 25-mer). For the current 
method, although the polymerizable phosphoramidite is needed in each synthetic cycle and 
impurities other than failure sequences have to be removed by n-BuOH precipitation, it has 
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significant advantages. The polymerizable phosphoramidite is far less expensive, and there 
is no need to cleave ODN from polymer. These two features make the current method far 
more convenient and less expensive to execute. Therefore, this method is highly suitable 
for purification of short ODN (shorter than 25-mer) on any scale. 
 
4.3 Conclusion 
We have developed a new method for ODN purification. This method does not 
need any chromatography or expensive reagents, and purification is achieved by simple 
operations such as shaking and extraction. Therefore, it is suitable for purification of large 
scale ON drugs. Studies on extending this method to purify other synthetic oligomers such 
as peptides are underway. 
 
4.4 Experimental Section 
General experimental 
ODNs were synthesized on a standard ABI 394 solid phase synthesizer. MALDI-
TOF mass spectra were obtained on a Shimadzu Biotech Axima CFRplus spectrometer. 
HPLC was performed on a JASCO LC-2000Plus System: pump, PU-2089Plus Quaternary 
Gradient; detector UV-2075Plus. A C-???????????????????????????????????????????????????
100 Å, 250 × 3.20 mm) was used. Solvent A: 0.1 M triethylammonium acetate, 5% 
acetonitrile. Solvent B: 90% acetonitrile. All profiles were generated by detection of 
absorbance of ODN at 260 nm using the linear gradient solvent system: solvent B (0%-
45%) in solvent A over 60 min followed by solvent B (45%-100%) in solvent A over 20 
min at a flow rate of 0.5 mL/min. Succinic ester linked DMTr-dT-lcaa-CPG (pore size 
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1000 Å ) and 5’-DMTr, 2-cyanoethyl phosphoramidites acetyl-dC, Pac-dA, 4-isopropyl-
Pac-dG and dT were purchased from Glen Research, Inc. DSalt ™ dextran desalting 
column (5K MWCO) was purchased from Pierce Biotechnology, Inc. 
 
Synthesis of phosphoramidite 4.1 
NC(CH2)2OP[N(i-Pr)2]2
1H-tetrazole, CH2Cl2 H
N
O
O
P N
O
NC
H
N
O
OH
H2N OH
Saturated Na2CO3, 
CH2Cl2, 3 h
Cl
O
93 %
4.1
4.2 4.3
 
 
Compound 4.1 is known.16 We used a different method to prepare 4.3, and only this 
step is described here. Compound 4.2 (5.0 g, 42.7 mmol), saturated Na2CO3 solution (50 
mL) and CH2Cl2 (150 mL) were charged into a round bottom flask, and cooled to 0 ºC. To 
the solution was added the solution of methacryloyl chloride (4.46 g, 42.7 mmol) in CH2Cl2 
(50 mL) dropwise with efficient stirring via an addition funnel. After addition, the mixture 
was stirred at rt for 3 h, and then transferred into a separation funnel. The organic layer was 
separated. The aqueous phase was extracted with CH2Cl2 for three times. The combined 
organic phase was dried over anhydrous Na2SO4, and filtered. The solution was 
concentrated to give a sticky liquid (not completely dry). Ether was added until white solids 
appeared, which was re-dissolved by adding CH2Cl2. To make the solution more dilute, 
hexanes and more CH2Cl2 were added. The solution was then put in a freezer (-20 ºC) for 
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12 h. Compound 4.3 was obtained as a colorless crystal: 7.33 g, 93% yield. If the compound 
melts at rt, a second crystallization from CH2Cl2/hexanes may be desirable. 
 
Synthesis of ODN 4.4  
3´ HO-TCGCCAGATTCGTCGTTAC-OH 5´ (4.4) 
ODN 4.4 was synthesized on a standard ABI 394 solid phase synthesizer using 
standard phosphoramidite chemistry under UltraMild conditions on controlled pore glass 
(CPG, ??????????????? ??????????????????????? ?????????????????????????? ??????????????????
the ODN to CPG. The phosphoramidite monomers used were Pac-dA-CE, Ac-dC-CE, i-
Pr-Pac-dGCEanddT-CE. A 0.2 M solution of the polymerizable capping phosphoramidite 
4.1 in acetonitrile was placed on the 5th bottle position, which is normally used for 
incorporating an additional base into ODN. The two bottles normally used to supply Ac2O 
capping reagents were empty. The synthesis was accomplished using the synthetic cycle 
shown in appendix B. In this synthesis, the capping failure sequences step was achieved 
using the polymerizable phosphoramidite 4.1 with 1H-tetrazole as the activator. The 
activator was from the same bottle that provided 1H-tetrazole for the coupling steps. To 
ensure complete capping, 4.1 and tetrazole were delivered to the synthesis column four 
times instead of two times normally used for standard nucleobase coupling (we found that 
capping two times were not enough for complete capping under the conditions we used. 
This can be seen in Figure B.7 of Appendix B), where the small peaks before the major 
full-length peak are un-capped failure sequences). Between each delivery, a waiting time 
of 15 seconds was applied. The oxidation of the phosphitetriesters between the capping 
agent and failure sequences was carried out for three times. In the last synthetic cycle, the 
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DMTr group was removed. Cleavage and deprotection were carried out on the synthesizer 
with concentrated NH4OH (900 min × 4) at rt. The ODN solution was distributed equally 
into four Eppendorf tubes (1.5 mL), and dried in a SpeedVac, separately (each portion 
contained ~50 nmol ODN, P1-P4). P1 ???????????????????????? ?????????????????????????
was injected into RP HPLC to generate trace in Figure 4.2. The full-length sequence 
appeared at ~19 minutes. The failure sequences were at ~20 minutes. The small peaks at 
around 10, 28, and 56 minutes were probably due to the small molecules from protecting 
groups. The very small peaks, which could be hardly seen in Figure 4.2 at the left of the 
full-length sequence, might be resulted from un-capped failure sequences, deletion 
sequences, or damaged sequences. 
 
Polymerization of failure sequences  
?????????????????????????????????P1 was transferred into a 2-necked round bottom 
flask. The Eppendorf tube was was???? ???? ??????????????????????washes were also placed 
into the same flask. To the flask was added the pre-formed polymerization solution [250 
???? N,N-dimethylacrylamide 1.69 M, N,N´-methylenebis(acrylamide) 16.9 mM; the 
solution could be stored at -20 °C in dark for 1 month]. The flask was flushed with nitrogen 
for 2 min with gentle stirring. (NH4)S2O8 ?????? ?? ???? ???? N,N,N´,N´- 
tetramethyleth???????????????????????????????????????????????lly via pipettes under 
positive nitrogen pressure. The solution was stirred gently under nitrogen at rt. A gel, which 
was the ODN failure sequences-polyacrylamide conjugate 4.6, was formed within 30 min. 
The gel was allowed to stand for another 30 min to ensure completion of polymerization. 
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Extraction of full-length sequence 
To the gel, which was broken into several pieces, was ??????????????????????????
mixture was stirred gently (shaking should be better) at rt for 3 h. The supernatant was 
transferred into an Eppendorf tube. The gel was further extracted with water for two times 
???????????????????????????????? h). The supernatants were combined and evaporated into 
??????????????????????????????? ???????????????????????????? injected into HPLC to 
generate trace in Figure 4.3. As shown, the failure sequences were removed, but the full-
length sequence appeared as four peaks. The small peaks resulted from small molecules 
from protecting groups also remained as expected. 
 
Size exclusion chromatography to remove small molecules 
A 10 mL D-Salt™ dextran desalting column (5K MWCO) was used. The column 
???????????????????????????? ??????????????????????????????????????????????4.4 was 
loaded to the top of the column. The Eppendorf tube ???? ?????? ???? ???????????????????
and the washes were also loaded to the column. The column was washed with 1.59 mL 
water. This first 2 mL eluent did not contain any ODN. The elution was continued and the 
next 5 mL was collected and evaporated to dryness. The residue ????????????????????????
??????????????????????????????????????????????????????a, Figure 4.4. As shown, the small 
molecules from protecting groups were removed. The four peaks at around 19 min were 
merged into three peaks. The desalting column was recovered by washing with water (20 
mL), and was stored in 0.02% NaN3 solution.  
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Treating with concentrated NH4OH 
???? ?????????? ??? ??? ????????? ??? ???? 4.4 was evaporated to dryness in an 
Eppendorf tube. Concentrated NH4???????????? ?????ded. The solution was heated to 80 
ºC for 15 min in a sand bath. After evaporation to dryness, the residue was dissolved into 
?????? ???????????? ????????????????? ??????????????????????b, Figure 4.4. As shown, only 
one peak is observed, and the ODN is pure. The recovery yield of the purification process 
(polymerization, extraction, size exclusion chromatography and NH4OH treatment) was 
determined to be 83% by comparing the area of the peak in trace b, Figure 4.4 with the area 
of the peak in Figure 4.1 at ~19 min. 
 
Identification of ODN 4.4  
The authentic ODN of 4.4 was synthesized using standard phosphoramidite 
????????????????????????????????????????? ??????????-on RP HPLC at The Midland Certified 
Reagent Company, Inc. (Midland, TX, USA). MALDI-TOF spectrum of the authentic 
ODN was also obtained at the company showing correct molecular weight: calculated for 
[M – H]? 6057, found 6060. At Michigan Tech, the authentic sample was divided equally 
into 10 portions (each portion contains ~100 nmol ODN assuming the yield for the 
synthesis and ?????????????????????????????????????????????????????????????????????????
was injected into RP HPLC to generate trace a (Figure 4.5). To compare ODN 4.4 
synthesized in our lab and purified using our catching failure sequences by polymerization 
technique with the authentic sample, 10 ??????????????????????????????????? trace a (Figure 
4.5) ?????????????????????????????????????????????????b (Figure 4.4) were mixed, and injected 
into RP HPLC to generate trace b (Figure 4.5). A single peak was observed showing the 
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two were identical. ODN 4.4 was also characterized with MALDI-TOF: calcd for [M – H]? 
6057, found: 6057 (See appendix B). 
 
ODN purification by polymerization of failure sequences and n-BuOH precipitation.  
The ODN 4.4 (P2???????????? ????????????????????????? ??????????L was injected 
into HPLC, which gave a trace exactly the same as Figure 4.1??????????????????????? ???
solution was subjected into the procedure of polymerization of failure sequences and 
extraction of full-length sequence as described above. The size exclusion chromatography 
step was not performed. To the full-length sequence, which contained ODNs and small 
organic molecules from protecting groups, was added concentrated NH4?????????????????
solution was vortexed shortly and then heated to 80 ºC for 30 min. This converted the 
modified ODNs to the un-modified one. After cooling to rt, n-BuOH (1 mL) was added. 
The mixture was vortexed for 30 sec and then centrifuged at 14.5K for 5 min. The 
supernatant was removed. The residue was re-dissolved into ?????? ???????????? n-BuOH 
was added. Votexed and centrifuged again, and the supernatant was removed. This 
removed the small organic molecules resulted from deprotection. The ODN was dissolved 
in 130 ??? ???????????? ????????????????? ????????????????Figure 4.6. As shown, the ODN 
is pure. The recovery yield of the procedure (polymerization, extraction, NH4OH treatment 
and n-BuOH precipitation) was determined to be 85% by comparing the area of the peak 
in Figure 4.6 with the peak area in Figure 4.1 at ~19 min. 
 
 
 
128 
Acknowledgements 
 Financial support from US NSF (CHE-0647129), Michigan Universities 
Commercialization Initiative, MTU Chemistry Department and Biotech Research Center, 
and The Royal Thai Government Scholarship (S. F.); the assistance from Mr. Jerry L. Lutz 
(NMR), Mr. Shane Crist (computation), and Mr. Dean W. Seppala (electronics) are 
gratefully acknowledged. 
 
[Fang, S.; Fueangfung, S.; Lin, X.; Zhang, X.; Mai, W.; Bi, L.; Green, S. A., Synthetic 
oligodeoxynucleotide purification by polymerization of failure sequences. Chemical 
Communications 2011, 47 (4), 1345-1347.] - Reproduced by permission of The Royal 
Society of Chemistry 
http://pubs.rsc.org/en/content/articlelanding/2011/cc/c0cc04374e#!divAbstract 
  
129 
References and Notes 
1.  Beaucage, S. L.; Bergstrom, D. E.; Glick, G. D.; Jones, R. A. In Current 
Protocols in Nucleic Acid Chemistry, John Wiley & Sons, Inc.: 2000. 
2.  (a) Beaucage, S. L. Solid-phase synthesis of siRNA oligonucleotides. Current 
Opinion on Drug Discovery Development 2008, 11, 203–216; (b) Schulte, M.; Luhring, 
N.; Keil, A.; Sanghvi, Y.S. Purification of DMT-On Oligonucleotide by Simulated 
Moving-Bed (SMB) Chromatography. Organic Process Research Development 2005, 9, 
212–215. 
3.  (a) Aitken, S.; Anderson, E., OligoPrep PVA Support for Oligonucleotide 
????????????????????????????????????????????????Nucleosides, Nucleotides and Nucleic 
Acids 2007, 26 (8-9), 931-934; (b) Sanghvi, Y. S.; Guo, Z.; Pfundheller, H. M.; Converso, 
A., Improved Process for the Preparation of Nucleosidic Phosphoramidites Using a Safer 
and Cheaper Activator. Organic Process Research & Development 2000, 4 (3), 175-181. 
4.  Pearson, W. H.; Berry, D. A.; Stoy, P.; Jung, K.-Y.; Sercel, A. D., Fluorous Affinity 
Purification of Oligonucleotides. The Journal of Organic Chemistry 2005, 70 (18), 7114-
7122. 
5. Deshmukh, R. R.; Miller, J. E.; De Leon, P.; Leitch, W. E.; Cole, D. L.; Sanghvi, 
Y. S., Process Development for Purification of Therapeutic Antisense Oligonucleotides by 
Anion-Exchange Chromatography. Organic Process Research Development 2000, 4, 205–
213. 
6.  (a) ?????? ???? ??????????? ??? ???? ??????????? ??-end biotinylation and affinity 
purification of synthetic RNA. Tetrahedron Letters 2004, 45 (43), 7987-7990; (b) Fang, 
130 
S.; Bergstrom, D. E., Fluoride-??????????????????????????????????????????????-end-labeling 
and affinity purification of synthetic oligonucleotides. Nucleic Acids Research 2003, 31 
(2), 708-715; (c) Fang, S.; Bergstrom, D. E., Reversible Biotinylation Phosphoramidite for 
5‘-End-Labeling, Phosphorylation, and Affinity Purification of Synthetic 
Oligonucleotides. Bioconjugate Chemistry 2002, 14 (1), 80-85 
7.  Beller, C.; Bannwarth, W., Noncovalent Attachment of Nucleotides by Fluorous-
Fluorous Interactions: Application to a Simple Purification Principle for Synthetic DNA 
Fragments. Helvetica Chimica Acta 2005, 88 (1), 171-179. 
8.  Sproat, B. S.; Rupp, T.; Menhardt, N.; Keane, D.; Beijer, B., Fast and simple 
purification of chemically modified hammerhead ribozymes using a lipophilic capture tag. 
Nucleic Acids Research 1999, 27 (8), 1950-1955 
9.  Pieken, W.; Wolter, A.; Leuck, M., Methods for the integrated synthesis and 
purification of oligonucleotides. U.S. Patent US20030195351 A1: 2003. 
10.  Fang, S.; Fueangfung, S., Scalable Synthetic Oligodeoxynucleotide Purification 
with Use of a Catching by Polymerization, Washing, and Releasing Approach. Organic 
Letters 2010, 12 (16), 3720–3723. 
11.  Sawadogo, M.; Dyke, M. W. V., A rapid method for the purification of deprotected 
oligodeoxynucleotides. Nucleic Acids Research 1991, 19 (3), 674. 
12.  LeProust, E. M.; Peck, B. J.; Spirin, K.; McCuen, H. B.; Moore, B.; Namsaraev, 
E.; Caruthers, M. H., Synthesis of high-quality libraries of long (150-mer) oligonucleotides 
by a novel depurination controlled process. Nucleic Acids Research 2010, 38 (8), 2522–
2540. 
131 
13.  In our previous studies, conjugate addition of failure sequences to N,N´-
dimethylacrylamide was not observed. One possibility is that the reaction requires the ODN 
to adopt higher order structures, which can only be assumed by the full-length sequence. 
14.  Standing at rt overnight could not completely reverse the reaction. 
15.  The very small peaks before that of the full-length sequence, which could hardly 
be seen, could not be removed using this technique. 
16. Zhu, Z.; Wu, C.; Liu, H.; Zou, Y.; Zhang, X.; Kang, H.; Yang, C. J.; Tan, W., An 
Aptamer Cross-Linked Hydrogel as a Colorimetric Platform for Visual Detection. 
Angewandte Chemie International Edition 2010, 49 (6), 1052-1056. 
 
 
 
 
 
 
 
 
 
 
 
132 
Chapter 5 
Synthetic 5´-Phosphorylated Oligodeoxynucleotide Purification through 
Catching Full-length Sequences by Polymerization* 
 
Yinan Yuan,ab Suntara Fueangfung, aXi Lin,a DurgaPokharel,a and Shiyue Fanga 
 
aDepartment of Chemistry, Michigan Technological University, 1400 Townsend Drive, 
Houghton, Michigan 49931, USA 
bSchool of Forest Resources and Environmental Science, Michigan Technological 
University, 1400 Townsend Drive, Houghton, Michigan 49931, USA 
Email: shifang@mtu.edu 
 
 
 
 
 
 
      
*This material contained in this chapter was previously published in RSC Advances, 2012, 2, 2803-2808 -- 
Reproduced by permission of The Royal Society of Chemistry. See Appendix D. Permission from 
publishers. 
133 
Abstract 
The readily scalable catching by polymerization purification technology has been 
further advanced to purify 5´-phosphorylated synthetic oligodeoxynucleotides (ODNs). 
The new technology utilizes a phosphoramidite that contains a fluoride-cleavable 
diisopropylsilyl acetal linker and a polymerizable methacrylamide group, and is capable of 
phosphorylation of ODN. For purification, the phosphoramidite was coupled to the 5´-end 
of full-length ODN on a synthesizer. Because failure sequences were capped in each 
synthetic cycle, only the full-length sequences were phosphinylated and acrylated. After 
cleavage and deprotection, the crude ODN was subjected to polymerization under typical 
acrylamide gel formation conditions. The full-length ODN was incorporated into polymer. 
The failure sequences and other impurities were simply removed by washing with water. 
Pure full-length ODN that contained a 5´-phosphate group was cleaved from the polymer 
with HF-pyridine. Reversed-phase (RP) HPLC showed that the ODN was pure, and the 
recovery yield was higher than that of typical preparative HPLC purification. 
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5.1 Introduction 
Synthetic oligonucleotides (ONs) including ODNs and oligoribonucleotides and 
their unnatural analogs have found wide applications in molecular biology and other 
scientific areas.1-8 These ONs are synthesized on an automated synthesizer using protected 
nucleoside phosphoramidite monomers.9 Typically, the first monomer is anchored to a 
solid support via its 3´-OH group through a cleavable linker. Phosphoramidite monomers 
are coupled to the 5´-OH in a stepwise fashion. Each synthetic cycle consists of 
detritylation, coupling, capping and oxidation steps, which finishes the addition of one 
nucleoside. Excess reagents and side products are washed away after each step while the 
nascent ON remains on the solid support. Normally, the coupling step is highly efficient, 
but generation of truncated failure sequences is unavoidable. This problem is more serious 
for long ONs (more than 50-mer) and large-scale ON syntheses.10 To ease purification, the 
failure sequences are capped with reagents such as acetic anhydride so that they do not 
participate in reactions in the subsequent synthetic cycles. After synthesis, the ONs are 
cleaved from the solid support and fully deprotected. The crude ON, which mainly contains 
full-length ON, failure sequences and small organic molecule impurities resulting from 
deprotection, is then purified with various methods. The small organic molecules are easy 
to remove because they have very different physical properties from ONs. However, the 
separation of full-length sequence from the failure ones is difficult due to their identical 
physical properties. Currently used methods for ON purification include gel 
electrophoresis, RP HPLC, anion exchange HPLC, RP cartridge extraction, fluorous 
affinity extraction,10–11 biotin–avidin enabled affinity purification,12-14 and other 
techniques.15 All these methods have limitations as we discussed in a previous paper.16 
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Briefly, gel electrophoresis can only be used to purify minute quantities of ON. HPLC 
methods need expensive instrument, consume large volumes of buffer, are labor intensive, 
and are expensive to scale up. RP cartridge extraction gives less pure ON. Fluorous affinity 
extraction and biotin–avidin enabled affinity purification require solid phase extraction 
materials, which are normally not reusable. To solve the ON purification problem, we 
recently developed two methods that utilized the concept of catching by polymerization for 
ODN purification.16–17 In one method, the failure sequences were capped with an acrylated 
phosphoramidite in each synthetic cycle. After synthesis, purification was achieved by 
simply polymerizing the failure sequences.17 In the second method, the full-length 
sequences were coupled to an acrylated phosphoramidite. After synthesis, purification was 
achieved by polymerization of full-length sequences, washing away the impurities and 
cleaving pure ODN from polymer.16 In this chapter, we report our results on using the 
catching by polymerization technology to purify synthetic ODNs that contain a 5´-
phosphate group. 
 
5.2 Results and Discussion 
In some biological applications such as ligation of synthetic ODNs for gene 
synthesis,18 cloning,19 mutagenesis,20 and ligation chain reaction,21 a phosphate group at 
the 5´-end of ODN is required. This group can be installed via enzyme-catalyzed 
phosphorylation.19 A more convenient approach is to attach the group on an automated 
DNA synthesizer. Several reagents have been commercialized for the purpose.22–23 One 
example is the phosphoramidite of 4,4´-dimethoxytrityl (DMTr)-protected 
bis(hydroxymethyl)malonate.23 The DMTr group in this reagent serves as a hydrophobic 
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handle for RP HPLC purification after synthesis. At the end of purification, the group is 
removed and the phosphate group at the 5´-end of ODN is released under basic conditions. 
In this paper, we combine this chemical phosphorylation technology with our newly 
developed catching by polymerization ODN purification technology to develop a method 
for purification of 5´-phosphorylated ODN. The reagent we designed for this ODN 
phosphorylation and purification  
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Scheme 5.1. Synthesis of acylation and phosphinylation phosphoramidite 5.1 
 
application is phosphoramidite 5.1. Its synthesis is shown in Scheme 5.1. The easily 
accessible and known methacryloyl tertiary alcohol 5.216 was coupled to diethyl 
bis(hydroxymethyl) malonate with dichlorodiisopropylsilane to give 5.3. The alcohol 5.3 
was then phosphinylated to give the target phosphoramidite 5.1. To demonstrate the 
usefulness of the phosphorylation and purification technique, the acrylated ODN 5.4 (see 
Scheme 5.2) was synthesized on a DNA synthesizer. Typical UltraMild ODN synthesis 
conditions, which use the more base-labile phenoxyacetyl protecting groups and allow 
deprotection with concentrated ammonium hydroxide at room temperature (see 
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experimental section for details), were used. At the end of the synthesis, the 
phosphoramidite 5.1 was coupled to the 5´-end of the ODN for 5 min. Oxidation and 
capping in this cycle were carried out under normal conditions. The cleavage and 
deprotection were carried out on the synthesizer. The crude ODN contained the full-length 
sequence 5.4, and impurities, which included the failure sequences 5.5 and small molecules 
from protecting groups. Because the failure sequences were capped with phenoxyacetic 
anhydride (Pac2O) in each synthetic cycle, they did not react with the phosphoramidite 5.1, 
and did not contain a methacrylamide group. Only the full-length sequences were 
acrylated. The crude ODN was analyzed with RP HPLC. As shown in Figure 5.1, the 
failure sequences 5.5 appeared at around 19 min. Due to the relatively more hydrophobic 
tag at the 5´-end of 5.4, the full-length ODN had an unusually long retention time of 62 
min. The small peaks appearing at 31 and 59 min may be attributed to small molecules 
from protecting groups.  
 
 
 
 
 
 
 
Figure 5.1. RP HPLC profile of crude ODN 
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The crude ODN was subjected to polymerization under typical polyacrylamide gel 
formation conditions (Scheme 5.2). Specifically, N,N-dimethylacrylamide was used as the 
monomer, a small amount of N,N´-methylenebis(acrylamide) was used as the cross-linker, 
water was used as the solvent, and the polymerization was conveniently initiated with 
ammonium persulfate and N,N,N´,N´-tetramethylethylenediamine (TMEDA). The reaction 
could tolerate air, but was conducted under nitrogen to minimize radical termination 
reactions by oxygen. The reaction was completed within 30 min at room temperature. To 
ensure that all monomers and cross-linkers were incorporated into the polymer, the reaction 
mixture was allowed to stand under nitrogen at room temperature for another 30 min. The 
acrylated full-length sequence 5.4 was incorporated into the polymer to give the ODN-
polymer conjugate 5.6 (Scheme 5.2). The failure sequences 5.5 and the impurities resulting 
from protecting groups remained in the polymer matrix, which were conveniently removed 
by extraction with water. The extracts were analyzed with RP HPLC to give a trace in 
Figure 5.2. Compared with the trace in Figure 5.1, the trace in Figure 4.2 did not have a 
peak at 62 min, which indicated that the full-length sequence was incorporated into 
polymer 5.6 efficiently.  
The ODN–polymer conjugate 5.6 was dried under vacuum. The intermediate ODN 
5.7 was cleaved from polymer with HF–pyridine complex in DMF. Excess HF was 
quenched with Me3SiOMe. The supernatant, which contained the ODN 5.7, excess 
Me3SiOMe, Me3SiF, (iPr)2SiF2, MeOH, and the solvent DMF, was removed. The polymer 
was washed with water. The supernatant and the washes were combined and evaporated to 
dryness leaving only the ODN 5.7. To remove the tag on the 5´-phosphate group, to 5.7 
was added concentrated ammonium hydroxide solution and heated to 80 ºC for 30 min. 
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Pure 5´-phosphorylated ODN 5.8 was obtained conveniently by direct n-BuOH 
precipitation from the solution. As shown in Figure 5.3, only one peak with a retention 
time of 19 min was observed. The recovery yield of the purification process was estimated 
to be 55% by comparing the area of the peak at 19 min in Figure 5.3 with the area of the 
peak at 62 min in Figure 5.1. The identity of the ODN was confirmed by MALDI-TOF MS 
analysis.  
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Scheme 5.2. Purification of 5´-phosphorylated ODN through catching full-length 
sequence by polymerization 
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Figure 5.2. RP HPLC profile of impurities including failure sequences 5.5 
 
 
Figure 5.3. RP HPLC profile of purified ODN 5.8 
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To further demonstrate the usefulness of this chemical phosphorylation and 
purification technology, the 61-mer ODN 5.9 (Figure 5.4), which is a portion of HIV 
protease gene, was synthesized and phosphinylated with phosphoramidite 5.1. To increase 
the yield of the synthesis, controlled pore glass (CPG) with a pore size of 2000 Å was used. 
Before starting the automated synthesis, the CPG was manually capped with Pac2O for 20 
min on the synthesizer. In addition, in the synthetic cycle, a 25-second waiting step was 
added after each delivery of coupling reagents (phosphoramidite and 1H-tetrazole) to the 
synthesis column. The capping step was performed two times. Following each capping 
step, a 50-second waiting step was added. Except for these modifications, the same 
synthesis procedure for ODN 5.4 was followed. The crude 5.9 was analyzed with RP-
HPLC (trace a, Figure 5.5), and purified with the catching by polymerization procedure as 
described for purification of 5.4. The purified 61-mer ODN 5.10 was analyzed with RP-
HPLC to give trace b (Figure 5.5). The recovering yield was estimated to be 65% by 
comparing the area of the peak at 20 min in the trace b with the peak area at 54 min in trace 
a (Figure 5.5).  
143 
5'HN
O
H
N
O
12 O Si O OO O
OO
P
O
OH
O
O
P
O
OHOGGA TGA TTA TGACATGGATAT CGA AA
ACC TAC ACC TGT CAA GAT AAT GGT CCA GGT CGG T OH
O
3'
OH
P
O
OHOGGA TGA TTA TGACATGGATAT CGA AAT
ACC TAC ACC TGT CAA GAT AAT GGT CCA GGT CGG T OH
3'
5'
5.9
5.10
N
NH
O
O
 
Figure 5.4. Sequence of ODN 5.9, and 5.10 
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Figure 5.5. RP HPLC profiles: (a) crude 61-mer ODN 5.9; (b) purified 61-mer ODN 5.10 
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modifications, all other reagents and conditions including the synthesis cycle are the same 
as those for the synthesis of 5.4. ODN 5.11 was cleaved from CPG with concentrated 
ammonium hydroxide at room temperature. The solution was then heated to 55 ºC for 8 h 
to remove protecting groups. The crude 5.11 was analyzed with HPLC (trace a, Figure 5.7) 
and purified with the catching by polymerization procedure as described for purification of 
5.4. The purified 25-mer ODN 5.12 (Figure 5.6) was analyzed with HPLC to give trace b 
(Figure 5.7). The recovering yield was estimated to be 79% by comparing the area of the 
peak at 18 min in trace b (Figure 5.7) with that of the peak at 58 min in the trace a (Figure 
5.7). 
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Figure 5.6. Sequence of ODN 5.11, and 5.12 
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Figure 5.7. RP HPLC profiles: (a) crude 25-mer ODN 5.11; (b) purified 25-mer ODN 
5.12  
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and deprotection as usual. (3) Subject the crude ODN to polymerization. (4) Wash the 
polymer with water. (5) Cleave ODN from the polymer. (6) Treat ODN with concentrated 
ammonium hydroxide shortly and precipitate ODN with n-BuOH. Several advantages of 
this technology are remarkable. When compared with HPLC, this technology requires 
minimum volume of solvent; the cost of the HPLC instrument and its maintenance fee can 
also be saved. When compared with fluorous affinity purification and biotin–streptavidin 
enabled affinity purification methodologies, which are also efficient and convenient, this 
new technology does not require any solid phase extraction material. The chemicals for the 
polymerization reaction are all commercially available, inexpensive, and can be stored for 
extended periods of time under suitable conditions. These materials are only needed in 
small quantities. The most significant advantage of the new technology is that it can be 
readily scaled up. Because there is no need of any type of chromatography, and purification 
is achieved by simple manipulations such as shaking and extraction, large quantities of 
ODN can be purified in each batch. This can be easily envisioned by the fact that there is 
virtually no cost difference between purification of 1 mg of ODN and purification of 1 g 
of ODN. If any other methods are used, the difference could be enormous. Due to these 
advantages, we expect that the technology presented in this paper will be widely used in 
industry and academia for the production of pure 5´-phosphorylated ODNs. 
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5.3 Conclusions 
In conclusion, by combining a commercialized chemical phosphorylation 
technique and our newly developed ODN purification methodology, we have developed a 
new technology for the purification of synthetic 5´-phosphorylated ODN. The technology 
is simple, convenient, inexpensive, and highly efficient. It may be readily scaled up and 
affords pure ODN at both small and large scales. We believe that it will provide a more 
affordable way for scientists to obtain 5´-phosphorylated ODNs for applications in 
chemistry, biology and medicine. 
 
5.4 Experimental 
General 
All reactions were performed in oven-dried glassware under a nitrogen atmosphere 
using standard Schlenk techniques. Reagents and solvents available from commercial 
sources were used as received unless otherwise noted. CH2Cl2 was distilled over CaH2. 
Thin layer chromatography (TLC) was performed using Sigma-Aldrich TLC plates, silica 
gel 60F-254 over glass support, 0.25 mm thickness. Flash column chromatography was 
performed using Selecto Scientific silica gel, particle size 32–63 mm. 1H, 13C and 31P NMR 
spectra were measured on a Varian UNITY INOVA spectrometer at 400, 100 and 162 
MHz, respectivel??????????????????????? ????????????????????????????????????????????????????
CHCl3 ??????????????????1H and CDCl3 at 77.00 ppm for 13C) and H3PO4 ???????????????
for 31P). High resolution mass spectra were obtained on a Finnigan Mat 95XL spectrometer. 
MALDI-TOF mass spectrum was obtained on a Shimadzu Biotech Axima CFRplus 
spectrometer. ODNs were synthesized on an ABI 394 solid phase synthesizer. HPLC was 
149 
performed on a JASCO LC-2000Plus System, Pump PU- 2089Plus Quaternary Gradient 
Pump, Detector UV-2075Plus. C-18 RP analytical column (5 mm diameter, 100 Å, 250 × 
3.20 mm) was used. Solvent A: 0.1 M triethylammonium acetate, 5% acetonitrile; solvent 
B: 90% acetonitrile. All profiles were generated by detection of absorbance of DNA at 260 
nm using the linear gradient solvent system: solvent B (0–45%) in solvent A over 60 min 
followed by solvent B (45%–100%) in solvent A over 20 min at a flow rate of 0.5 mL min-
1. THF/pyridine/Pac2O, THF/pyridine/Ac2O, succinic ester linked DMTr-dTlcaa- CPG 
(pore sizes 1000 Å and 2000 Å ; lcaa = long chain alkylamino), 5´-DMTr 2-cyanoethyl 
phosphoramidites acetyl-dC, Pac-dA (Pac = phenoxyacetyl), Bz-dA, 4-isopropyl-Pac-dG, 
i-Bu-dG and dT, and other commonly used solid phase DNA synthesis reagents were 
purchased from Glen Research, Inc. 
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H
N
O
H
N
O
12 OH
1. (TfO)2Si(iPr)2, DIEA
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H
N
O
H
N
O
12 O Si O OHO O
OO
5.2 5.3
42 %  
A round-bottomed flask containing compound 5.216 (200 mg, 0.49 mmol, 1.0 eq.) 
and a magnetic stirring bar was evacuated and then refilled with nitrogen. The evacuation 
and nitrogen filling cycle was repeated for two more times. Dry DMF (2 mL) and 
diisopropylethylamine (254 mL, 1.46 mmol, 3.0 eq.) were added via syringes. The mixture 
was cooled to 0 uC. Diisopropylsilyl bis(trifluoromethane sulfonate) (144 mL, 0.487 
mmol, 1.0 eq.) in dry DMF (1 mL) was added via a syringe in one portion at 0 ºC. The 
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solution was stirred at 0 ºC for 1 h and rt for 2 h. Imidazole (50 mg, 0.73 mmol, 1.5 eq.) in 
dry DMF (1 mL) was added via a syringe. The solution was stirred for 1 h, and then added 
to a flask containing diethyl bis(hydroxymethyl)malonate (107 mg, 0.487 mmol, 1.0 eq.), 
imidazole (33 mg, 0.487 mmol, 1.0 eq.) and DMF (2 mL) at 0 ºC via a cannula slowly. The 
reaction mixture was stirred at 0 ºC for 4 h, and then quenched with 5% NaHCO3 (0 ºC, 50 
mL). EtOAc (0 ºC, 30 mL) was added, and the phases were separated. The aqueous phase 
was extracted with EtOAc (0 ºC, 30 mL × 3). The combined organic phase was dried over 
anhydrous Na2SO4 and filtered. The filtrate was evaporated under reduced pressure to give 
a yellow oil. Purification with flash column chromatography (SiO2, hexanes/EtOAc, 3 : 1 
to 1 : 1) gave 5.3 as a pale yellow oil (151 mg, 42%): Rf 0.60 (SiO2, hexanes/EtOAc = 1 : 
2); 1H NMR (400 MHz, CDCl3???????????????????????????????????????????–5.609 (m, 1H), 
5.25–5.24 (m, 1H), 4.23 (s, 2H), 4.21–4.08 (m, 6H), 3.86 (br s, 1H), 3.26–3.21 (m, 2H), 
3.18–3.13 (m, 2H), 2.26–2.14 (m, 2H), 1.91–1.90 (m, 3H), 1.83–1.77 (m, 2H), 1.53– 1.37 
(m, 8H), 1.25–1.19 (m, 22H), 0.99–0.95 (m, 14H), 0.83–0.76 (m, 6H); 13C NMR (100 
MHz, CDCl3????????????????????????????????????????????????????????????????????????????????
34.7, 31.6, 31.3, 31.1, 30.9, 29.7, 29.6, 29.4, 27.1, 18.9, 18.1, 17.9, 14.4, 14.2, 13.7, 8.5; 
HRMS (ESI, [M+Na]+) calculated for C39H74N2NaO9Si 765.5061, found 765.5069. 
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Synthesis of phosphoramidite 5.1 
1H-tetrazole, CH2Cl2
NC(CH2)2OP[N(iPr)2]2 HN
O
H
N
O
12 O Si O OO O
OO
P
O
N
CN
5.1
H
N
O
H
N
O
12 O Si O OHO O
OO
5.3 99 %
 
A round-bottomed flask containing 5.3 (119 mg, 0.16 mmol, 1.0 eq.) and a 
magnetic stirring bar was evacuated and then refilled with nitrogen. The evacuation and 
nitrogen-filling cycle was repeated for two more times. Dry CH2Cl2 (5 mL) and 2-
cyanoethyl-N,N,N´,N´-tetraisopropylphosphoramidite (60 mL, 0.176 mmol, 1.1 eq.) were 
then added via syringes. A 
1H-tetrazole solution in CH3CN (0.45 M, 391 mL, 0.176 mmol, 1.1 eq.) was added via a 
syringe in one portion. After stirring at rt for 2 h, the reaction mixture was concentrated to 
dryness under reduced pressure. The residue was purified with flash column 
chromatography (SiO2, hexanes/EtOAc/Et3N = 3 : 1 : 1) giving 5.1 as a colorless oil (150 
mg, 99%): Rf 0.40 (SiO2, hexanes/EtOAc/ Et3N = 3 : 1 : 1); 1H NMR (400 MHz, CDCl3????
6.00 (br s, 1H), 5.85 (br s, 1H), 5.64–5.60 (m, 1H), 5.263–5.257 (m, 1H), 4.23–4.10 (m, 
8H), 3.80–3.71 (m, 2H), 3.56–3.47 (m, 2H), 3.28–3.23 (m, 2H), 3.20–3.15 (m, 2H), 2.58–
2.55 (m, 2H), 2.27–2.15 (m, 2H), 1.921– 1.920 (m, 3H), 1.85–1.74 (m, 2H), 1.56–1.38 (m, 
8H), 1.24–1.18 (m, 24H), 1.14–1.11 (m, 10H), 1.00–0.98 (m, 14H), 0.82 (t, 6H, J = 7.6 
Hz); 13C NMR (100 MHz, CDCl3?????????????????????????????????????????????????????????
61.1, 61.0, 58.7, 58.5, 43.4, 43.3, 39.9, 39.7, 35.6, 34.2, 31.9, 31.1, 29.8, 29.71, 29.67, 
29.59, 29.50, 29.46, 27.1, 24.8, 24.74, 24.69, 24.66, 20.55, 20.49, 18.9, 18.1, 17.9, 14.4, 
14.1, 13.6, 8.53; 31P NMR (162 MHz, CDCl3?????????? 
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ODN 5.4 synthesis, cleavage and deprotection 
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The 20-mer 5´-acrylated and phosphorylated ODN 5.4 was synthesized on an ABI 
DNA/RNA synthesizer at 1 mmol scale. The solid support was lcaa-CPG with a pore size 
of 1000 Å. The ODN was anchored to the support through a succinic ester linkage. The 
following 5´-DMTr-protected 2-cyanoethyl phosphoramidite monomers were used for the 
synthesis: Pac-dA, 4-isopropyl-Pac-dG, Ac-dC and dT. THF/pyridine/Pac2O was used as 
the capping reagent. The manufacturer recommended synthetic cycle was followed except 
that the phosphoramidite 5.1 was coupled for 5 min. After synthesis, the ODN was cleaved 
from CPG with concentrated NH4OH at rt and allowed to stand under these conditions for 
8 h. The solution of crude ODN was divided into 10 equal portions, and evaporated to 
dryness in 10 Eppendorf tubes in a vacuum SpeedVac concentrator. One portion was 
dissolved in 150 mL water, of which 20 mL was injected into HPLC to generate trace in 
Figure 5.1.  
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Polymerization of full-length ODN 5.4-synthesis of ODN-polyacrylamide conjugate 
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The remaining 130 mL solution of the crude ODN 5.4 was transferred into a 2-
necked round-bottomed flask. The Eppendorf tube was washed with water (40 mL × 3) and 
the washes were added to the flask. A polymerization solution [250 mL; N,N-
dimethylacrylamide (1.69 M) and N,N´-methylenebis(acrylamide) (16.9 mM) in water; the 
solution can be pre-prepared and stored at -20 ºC in the dark for at least 1 month] was added 
via a pipette. The mixture was gently stirred under a nitrogen flow for 2 min. The solution 
of (NH4)2S2O4 (10%, 5 mL) was then added via a pipette, which was followed by 
N,N,N´,N´-tetramethylethylenediamine (TMEDA, 5 mL). The mixture was stirred gently 
under nitrogen at rt for 30 min. The ODN–polyacrylamide conjugate 5.6 was formed. The 
failure sequences 5.5 remained in solution (Scheme 4.2). The gel was allowed to stand for 
another 30 min to ensure complete polymerization. 
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Removal of failure sequences and other impurities 
To the ODN–polymer conjugate 5.6 in the round-bottomed flask was added 3 mL 
water. The content was gently shaken at rt overnight. The supernatant, which contained the 
failure sequences 5.5 and other impurities, was removed with a pipette. The gel was further 
washed with water (2 mL × 3; 2 h each time). The supernatant and the washes were 
combined and evaporated to dryness. The residue was dissolved in 130 mL water, of which 
20 mL was injected into HPLC to generate trace in Figure 5.2.  
 
Cleavage of full-length ODN from polymer and releasing the 5´-phosphate group  
The gel in the round-bottomed flask was dried under vacuum. Dry DMF (2 mL) 
was added via a pipette, which was followed by HF–pyridine complex (60 mL). The 
mixture was shaken gently under nitrogen for 5 h. Me3SiOMe (500 mL) was then added. 
After shaking for 15 min, the supernatant was transferred to Eppendorf tubes. The gel was 
extracted with water (2 mL 63 at rt; 12 h, 2 h, 2 h, respectively). The supernatant and the 
extracts were evaporated to dryness in a SpeedVac vacuum concentrator and were 
combined to give ODN 5.7 (Scheme 5.2). To deprotect the 5´-phosphate group of 5.7, 
concentrated NH4OH (~28%, 100 mL) was added. After a short vortex, the mixture was 
heated to 80 ºC for 30 min. After cooling to rt, n-BuOH (900 mL) was added. The mixture 
was vortexed for 30 s and then centrifuged at 14.5 K for 5 min. The supernatant was 
removed. The residue was further dried shortly in a SpeedVac. The ODN 5.8 was dissolved 
in 130 mL water, of which 20 mL was injected into HPLC to generate the profile (Figure 
5.3). The recovery yield of the purification process was estimated to be 55% by comparing 
the area of the peak in Figure 5.3 at 19 min with the peak area in Figure 5.1 at 62 min. 
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MALDI-TOF mass spectrum of ODN 5.8: calculated for [M-2H+Na]- 
C194H247N67NaO125P20 6159.0, found 6159.8.  
 
Synthesis and purification of the 61-mer ODN 5.10 
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For the solid phase synthesis, cleavage and deprotection of 5.9, the procedure for 
5.4 was followed except for the following modifications. CPG with a pore size of 2000 Å 
instead of 1000 Å was used. Before synthesis, the CPG was manually capped with Pac2O 
for 20 min on the synthesizer. In the synthetic cycle, a 25-second waiting step was added 
after each delivery of coupling reagents (phosphoramidite and tetrazole) to the synthesis 
column. An additional capping step was added, and after each capping step, a 50-second 
waiting step was added. The catching by polymerization procedure was exactly the same 
as described for 5.4. However, for RP HPLC analysis of 5.10, buffer A that contained 10% 
urea was used.  
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Synthesis and purification of the 25-mer ODN 5.12 using normal base protecting 
groups 
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For the solid phase synthesis, cleavage and deprotection of 5.11, the procedure for 
5.4 was followed except for the following modifications. The 5´-DMTr-protected 2-
cyanoethyl phosphoramidite monomers Bz-dA, i-Bu-dG, Ac-dC and dT were used. The 
capping agents were replaced with THF/pyridine/Ac2O. After cleaving the ODN from CPG 
with concentrated NH4OH at rt, the solution was heated to 55ºC for 8 h in a tightly capped 
vial. The catching by polymerization procedure was exactly the same as described for 5.4. 
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Chapter 6 
Future Research Plan 
 ODN purification technology has become vital for many research applications 
including ODN drug development and biological studies. In preceding chapters, we 
described our technology which is to purify synthetic ODN including catching the full-
length sequence and catching failure sequences. The principle is to use polymerization 
reaction to purify ODN, which is low cost and simple. Despite the fact that the technology 
is successful, there are some elements that we can improve the methods and extend this 
technology for the future.   
6.1 User-friendly cleavable linker for ODN Purification by Catching Full-length 
Sequence  
 The phosphoramidite monomer 3.1, which was described in chapter 3, has 
diisopropyl silyl acetal group as a cleavable linker. After polymerization and impurities 
removal, purified ODN was released from the gel under anhydrous conditions using HF-
pyridine. Although the results from the purification method were satisfactory, HF-pyridine 
might cause a problem when doing large-scale ODN purification because HF is corrosive 
and very toxic. In addition, cleavage will not be efficient if the gel still contains water. 
Thus, the procedure requires the step to remove water from the gel.  
 To simplify the method, the other phosphoramidite monomer is proposed in Figure 
6.1. The phosphoramidite 6.1 has a modified DMTr group as a cleavable linker. This can 
avoid using HF-pyridine. Unlike diisopropyl silyl acetal group, this modified DMTr can 
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be cleaved using weak acid (eg. CH3COOH). Also, it does not need to remove water from 
the gel before cleaving. The purification process is proposed in scheme 6.1. The compound 
6.1 would be coupled in the last cycle of ODN synthesis to get crude ODN (6.2 and 6.3). 
Then, 6.2 would be incorporated in the gel during polymerization. Once impurities are 
removed, weak acidic conditions would be used to cleave 6.4 to get pure 6.5.  
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Figure 6.1. Phosphoramidite 6.1 
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Scheme 6.1. Proposed ODN purification using phosphoramidite 6.1 
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6.2 Detailed Studies on ODN Purification by Capping Failure Sequences 
 In chapter 4, the phosphoramidite 4.1 was introduced for catching failure 
sequences. To continue further studies, the other three capping phosphoramidites would be 
designed to test capping efficiency and optimal time (Figure 6.2). The hypothesis is that 
ether oxygen atom in each compound can increase the solubility in organic solvent (eg. 
acetonitrile). Therefore, their reaction kinetics while capping might be better than 4.1.    
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Figure 6.2. New polymerizable capping phosphoramidites 
 Moreover, the detailed studies will also be focusing on diffusion speed and 
extraction efficiency of ODN from gel using different cross-linking ratio, purification of 
long sequence ODN, larger scale ODN purification, and polymerization of failure 
sequences in air. Finally, purified ODN will be tested for the stability under radical 
polymerization by complete enzymatic ODN digestion. All nucleosides from the digestion 
will be analyzed by RP HPLC.  
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6.3 Synthetic Peptide Purification using Polymerization Approach     
 Since synthetic peptides are beneficial to many research area, such as clinical trials, 
therapeutic   studies, and molecular biology, it is undeniable that peptide purification is 
essential for them. Therefore, purification methodology will be applied to synthetic 
peptides. In this case, both methods (Catching full-length peptide and catching failure 
sequences) will be planned for peptide purification.  
 For catching full-length peptide, compound 6.9 which consists of reactive p-
nitrophenyl carbonate, an acid-labile linker, and polymerizable group will be synthesized 
(Figure 6.3). This compound will be incorporated in the last cycle of peptide synthesis. 
Then, full-length peptide will be in the gel by polymerization. Impurities including failure 
sequences will be removed by washing. Purified peptide will be given by cleaving from 
the gel. For catching failure sequences, compound 6.10 will be used as a capping agent 
(Figure 6.4). All failure sequences will be capped with 6.10. Then, polymerization will 
remove failure sequences and give pure full-length peptide.  
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Figure A.1. 1H-NMR of compound 3.1  
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Figure A.2. 13C-NMR of compound 3.1
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Figure A.3. 31P-NMR of compound 3.1 
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Figure A.4. 1H-NMR of compound 3.2 
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Figure A.5. 13C-NMR of compound 3.2 
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Figure A.6. 1H-NMR of compound 3.3 
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Figure A.7. 13C-NMR of compound 3.3 
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Figure A.8. 1H-NMR of compound 3.4  
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Figure A.9. 13C-NMR of compound 3.4 
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Figure A.10. 1H-NMR of compound 3.5  
 
1 H
 N
M
R
 o
f c
om
po
un
d 
3.
5 
in
 C
D
3O
D
, 4
00
 M
H
z
N H
O
N H
O
10
O
S
i
O
O
O
H
N
N
H
O
O
3.
5
178 
Figure A.11. 13C-NMR of compound 3.5 
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Figure A.12. MALDI-TOF mass spectrum of ODN 3.9 purified using the catching by 
polymerization, washing and releasing approach 
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Calculated 5922,  
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Figure B.1. 1H-NMR of compound 4.1  
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Figure B.2. 13C-NMR of compound 4.1 
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Figure B.3. 31P-NMR of compound 4.1 
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Figure B.4. 1H-NMR of compound 4.3 
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Figure B.5. 13C-NMR of compound 4.3 
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Figure B.6.  MALDI-TOF mass spectrum of ODN 4.4 purified by polymerization of 
failure sequences 
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Figure B.7.  HPLC profile of crude ODN with two times capping instead of four times 
capping 
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Table B.1. ODN synthetic cycle using polymerizable phosphoramidite as capping 
agent 
ODN synthetic cycle using polymerizable phosphoramidite 4.1 as the capping agent 
Synthesizer: standard ABI 394 solid phase synthesizer; 4-column 8-base instrument 
Polymerizable capping agent: 0.2 M solution of 4.1 in acetonitrile, placed at the bottle 5 
position 
The bottles for normal Ac2O capping agents are empty 
Activator for the capping phosphoramidite: from the same bottle for the coupling step 
Synthesis scale: 0.2 μmol 
Column used: column 2 
Step number Function number Function name Step time 
1.  106 Begin  
2.  64 18 To waste 3.0 
3.  42 18 To column 10.0 
4.  2 Reverse flush 8.0 
5.  1 Block flush 4.0 
6.  101 Phos Prep 3.0 
7.  142 Column 2 on  
8.  64 18 To waste 4.0 
9.  1 Block flush 3.0 
189 
Step number Function number Function name Step time 
10.  111 Block vent 2.0 
11.  58 Tet to waste 1.7 
12.  33 B+Tet to column 2.0 
13.  34 Tet to column 1.0 
14.  33 B+Tet to column 1.5 
15.  43 Push to column  
16.  143 Column 2 off  
17.  103 wait 25.0 
18.  64 18 To waste 4.0 
19.  2 Reverse flush 5.0 
20.  1 Block flush 3.0 
21.  41 15 To column 8.0 
22.  64 18 To waste 4.0 
23.  1 Block flush 3.0 
24.  103 Wait 15.0 
25.  42 18 To column 10.0 
26.  4 Flush to waste 4.0 
27.  42 18 To column 10.0 
190 
Step number Function number Function name Step time 
28.  2 Reverse flush 5.0 
29.  1 Block flush 3.0 
30.  142 Column 2 on  
31.  64 18 To waste 4.0 
32.  1 Block flush 3.0 
33.  111 Block vent 2.0 
34.  58 Tet to waste 1.7 
35.  35 5+Tet to column 2.5 
36.  103 Wait 15.0 
37.  34 Tet to column 1.0 
38.  35 5+Tet to column 1.5 
39.  103 Wait 15.0 
40.  34 Tet to column 1.0 
41.  35 5+Tet to column 1.5 
42.  103 Wait 15.0 
43.  34 Tet to column 1.0 
44.  35 5+Tet to column 1.5 
45.  103 Wait 15.0 
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Step number Function number Function name Step time 
46.  43 Push to column  
47.  143 Column 2 off  
48.  103 Wait 30.0 
49.  142 Column 2 on  
50.  64 18 To waste 4.0 
51.  2 Reverse flush 5.0 
52.  1 Block flush 3.0 
53.  41 15 To column 12.0 
54.  103 Wait 22.0 
55.  41 15 To column 5.0 
56.  103 Wait 15.0 
57.  41 15 To column 5.0 
58.  64 18 To waste 4.0 
59.  1 Block flush 3.0 
60.  103 Wait 15.0 
61.  42 18 To column 10.0 
62.  4 Flush to waste 4.0 
63.  42 18 To column 10.0 
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Step number Function number Function name Step time 
64.  2 Reverse flush 5.0 
65.  1 Block flush 3.0 
66.  105 Start detrityl  
67.  64 18 To waste 4.0 
68.  42 18 To column 10.0 
69.  2 Reverse flush 5.0 
70.  1 Block flush 3.0 
71.  167 If monitoring  
72.  44 19 To column 25.0 
73.  40 14 To column 3.0 
74.  135 Monitor triyls  
75.  40 14 To column 25.0 
76.  136 Monitor noise  
77.  40 14 To column 10.0 
78.  137 Stop monitor  
79.  42 18 To column 10.0 
80.  2 Reverse flush 8.0 
81.  168 If not monitoring  
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Step number Function number Function name Step time 
82.  40 14 To column 6.0 
83.  3 Trityl flush 5.0 
84.  40 14 To column 6.0 
85.  103 Wait 5.0 
86.  3 Trityl flush 5.0 
87.  40 14 To column 6.0 
88.  103 Wait 5.0 
89.  3 Trityl flush 5.0 
90.  40 14 To column 6.0 
91.  103 Wait 5.0 
92.  3 Trityl flush 5.0 
93.  42 18 To column 10.0 
94.  3 Trityl flush 8.0 
95.  169 End monitoring  
96.  42 18 To column 8.0 
97.  2 Reverse flush 5.0 
98.  1 Block flush 4.0 
99.  107 End  
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Figure C.1. 1H-NMR of compound 5.1 
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Figure C.2. 13C-NMR of compound 5.1 
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Figure C.3. 31P-NMR of compound 5.1  
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Figure C.4. 1H-NMR of compound 5.3 
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Figure C.5. 13C-NMR of compound 5.3 
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Figure C.6. MALDI-TOF mass spectrum of ODN 5.8 purified by polymerization of 
failure sequences 
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Figure C.7. MALDI-TOF mass spectrum of ODN 5.8 (Expanded) purified by 
polymerization of failure sequences 
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